Inhibition of gliadin peptides

ABSTRACT

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.

PRIORITY

This application claims priority to U.S. Provisional Application No.61/050,915 filed May 6, 2008, which is hereby incorporated by referencein its entirety.

TECHNICAL FIELD OF THE INVENTION

This invention is related to the area of gastrointestinal inflammation.In particular, it relates to compounds and methods for the treatment ofgastrointestinal inflammation.

BACKGROUND OF THE INVENTION

Environmental stimuli, such as microorganisms and gluten, can lead toincreased permeability of biological barriers and initiate significantpathological events in the intestine, brain, heart, and other organs.The pathological consequences of such stimuli include the development ofinflammatory diseases. Such external stimuli are presumed to exertphysiological effects on biological barriers, possibly throughinteraction with specific cell surface receptors. However, themechanisms used remain unclear, and specific cell surface receptors haveyet to be confirmed.

Many inflammatory diseases, including those that are understood toinvolve increased permeability of biological barriers, are thought to beautoimmune. Such diseases include celiac disease, rheumatoid arthritis,multiple sclerosis, immune-mediated or type 1 diabetes mellitus,inflammatory bowel diseases, systemic lupus erythematosus, psoriasis,scleroderma, necrotizing enterocolitis and autoimmune thyroid diseases.Prolonged inflammation is often associated with these diseases, althoughthe inflammation is thought to be a sequela rather than a primarypathological insult.

Biological Barrier Dysfunction

Biological barrier function relies upon the structural and functionalintegrity of tight junctions (TJ), which are one of the hallmarks ofabsorptive and secretory epithelia. They act as a boundary thatphysically separates apical and basolateral compartments of epithelialcells, and they selectively regulate the passage of materials throughthe epithelia by controlling access to the space between the epithelialcells (the paracellular pathway). To meet the many diverse physiologicaland pathological challenges to which epithelia are subjected, the tightjunctions must be capable of rapid, physiologic, reversible, transient,energy dependent, and coordinated responses that require the presence ofa complex regulatory system. Examples of epithelia containing tightjunctions include, but are not limited to, the intestines (particularlythe small intestine), and the blood brain barrier.

In the absence of stimuli, tight junctions are closed restricting accessto the paracellular pathway. In the presence of stimuli, the tightjunctions are reversibly opened. Certain bacteria have been shown tohave toxins that stimulate the opening of tight junctions. Vibriocholerae infected with the filamentous bacteriophage CTX, produces atoxin (zonula occludens toxin, ZOT) that has been shown to cause openingof tight junctions. It has been shown that 6 His-AG, an N-terminaldeletion of ZOT in which the first 264 amino acids, have been deletedand replaced with a six histidine purification tag, retains the abilityto open tight junctions.

Physiological changes in paracellular permeability, which are due to TJregulation, can be measured as variations in transepithelialconductance. Such variations can usually be attributed to changes inparacellular permeability since the resistances of epithelial plasmamembranes are relatively high. TJ represent the major barrier in theparacellular pathway, and the electrical resistance of epithelialtissues seems to depend on their integrity.

Environmental stimuli, including for example, microorganisms and gluten,can increase permeability of biological barriers as measured by adecrease in transepithelial electrical resistance (TEER) (ex vivo) orthe Lactulose/mannitol test (in vivo). Such increases in barrierpermeability are due primarily to TJ rearrangements, and they arebelieved to underlie many diseases including a large number ofinflammatory conditions.

TJ dysfunction occurs in a variety of clinical conditions, includingfood allergies, infections of the gastrointestinal tract, autoimmunediseases, celiac disease and inflammatory bowel diseases. Healthy,mature gut mucosa with its intact tight junction serves as the mainbarrier to the passage of macromolecules. During the healthy state,small quantities of immunologically active antigens cross the gut hostbarrier. These antigens are absorbed across the mucosa through at leasttwo pathways. Up to 90% of the absorbed proteins cross the intestinalbarrier via the transcellular pathway, followed by lysosomal degradationthat converts proteins into smaller, non-immunogenic peptides. Theseresidual peptides are transported as intact proteins through theparacellular pathway, which mediates a subtle, but sophisticated,regulation of intercellular tight junction that leads to antigentolerance.

In normal bowels, the immune reaction is regulated to maintainhomeostasis of the gut. When TJ integrity is compromised, in prematureinfants or on exposure to environmental stimuli, radiation,chemotherapy, or toxins, a deleterious immune response to environmentalantigens may develop. This response can result in autoimmune diseasesand food allergies that lead to inflammation.

Inflammatory bowel disease (IBD) is a phrase used to describe aninappropriate immune response that occurs in the bowels of affectedindividuals. Two major types of IBD have been described: Crohn's diseaseand ulcerative colitis (UC). Both forms of IBD show abnormal profiles ofT cell mediated immunity. In the gut of Crohn's disease a strong Th1reaction is induced; the Th2 response is upregulated in the colon of UC.

The barrier function of the intestines is impaired in IBD. For example,Crohn's disease is associated with increased permeability of theintestinal barrier even in quiescent patients. A TNF-α-induced increasein intestinal epithelial tight junction (TJ) permeability has beenproposed to be an important proinflammatory mechanism contributing tointestinal inflammation in Crohn's disease and other inflammatoryconditions. Increased intestinal permeability during episodes of activedisease correlates with destruction or rearrangement of TJ proteincomplexes.

Examples of inflammatory diseases and disorders that may be treatedusing the instant invention include, for example, celiac disease,necrotizing enterocolitis, rheumatoid arthritis, multiple sclerosis,immune-mediated or type 1 diabetes mellitus, inflammatory bowel diseases(Crohn's disease and ulcerative colitis), systemic lupus erythematosus,psoriasis, scleroderma, and autoimmune thyroid diseases. Prolongedinflammation is often associated with these diseases, although theinflammation is thought to be a sequela rather than a primarypathological insult.

Other diseases and disorders associated with biological barrierdysfunction and which may be treated using the instant inventionsinclude, for example, celiac disease, asthma, acute lung injury, acuterespiratory distress syndrome, chronic obstructive pulmonary disease,inflammation (e.g., psoriasis and other inflammatory dermatoses),asthma, allergy, cell proliferative disorders (e.g., hyperproliferativeskin disorders including skin cancer), metastasis of cancer cells, iontransport disorders such as magnesium transport defects in the kidney,and exposure to Clostridium perfringens enterotoxin (CPE). autoimmuneencephalomyelitis, optic neuritis, progressive multifocalleukoencephalopathy (PML), primary biliary cirrhosis, IgA nephropathy,Wegener's granulomatosis, multiple sclerosis, scleroderma, systemicsclerosis, Hashimoto's thyroiditis (underactive thyroid), Graves'disease (overactive thyroid), autoimmune hepatitis, autoimmune inner eardisease, bullous pemphigoid, Devic's syndrome, Goodpasture's syndrome,Lambert-Eaton myasthenic syndrome (LEMS), autoimmune lymphproliferativesyndrome (ALPS), paraneoplastic syndromes, polyglandular autoimmunesyndromes (PGA), alopecia areata, gastrointestinal inflammation thatgives rise to increased intestinal permeability, intestinal conditionsthat cause protein losing enteropathy, C. difficile infection,enterocolitis, shigellosis, viral gastroenteritis, parasite infestation,bacterial overgrowth, Whipple's disease, diseases with mucosal erosionor ulcerations, gastritis, gastric cancer, collagenous colitis, andmucosal diseases without ulceration, Menetrier's disease, eosinophilicgastroenteritis, diseases marked by lymphatic obstruction, congenitalintestinal lymphangiectasia, sarcoidosis lymphoma, mesenterictuberculosis, after surgical correction of congenital heart disease, andfood allergies, primarily to milk.

Inflammation

Inflammation plays a central role in the pathology of disease conditionsthat adversely affect a considerable proportion of the population indeveloped countries. This process is mediated by cytokines, a system ofpolypeptides that enable one cell to signal to initiate events inanother cell that initiate inflammatory sequelae. Normally, the systemacts as part of a defensive reaction against infectious agents, harmfulenvironmental agents, or malignantly transformed cells. But wheninflammation exceeds the requirements of its defensive role, it caninitiate adverse clinical effects, such as arthritis, septic shock,inflammatory bowel disease, and a range of other human diseaseconditions.

Immune cells such as monocytes and macrophages secrete cytokinesincluding tumor necrosis factor-α (TNFα) and tumor necrosis factor-β(TNFβ) in response to endotoxin or other stimuli. Cells other thanmonocytes or macrophages also make cytokines including TNFα. Forexample, human non-monocytic tumor cell lines produce TNF. CD4⁺ and CD8⁺peripheral blood T lymphocytes and some cultured T and B cell lines alsoproduce TNFα. A large body of evidence associates cytokines such as TNFαwith infections, immune disorders, neoplastic pathologies, autoimmunepathologies and graft-versus host pathologies.

Small-molecule antirheumatic drugs such as methotrexate andsulfasalazine are insufficient to control inflammation in abouttwo-thirds of arthritis patients. New biological agents developed in thelast decade have proved to be effective for a majority of patientsunresponsive to traditional drugs. The target for such agents is oftenone of the cytokine pathways—either capturing the ligand conveying thesignal from one cell to another, or blocking the receptor at the surfaceof the effector cell, preventing transduction of the cytokine signal,thereby forestalling the inflammatory events.

A leading biological agent for treating inflammatory conditions isEnbrel™ (Etanercept), marketed by Amgen Corp. It is a chimeric moleculecomprising the extracellular portion of the human TNF receptor linked asa dimer to the IgG Fc region. The compound interferes with the bindingof TNF to cell-surface TNF receptors—showing the importance ofmodulating the TNF pathway for clinical therapy of inflammatoryconditions.

Other TNFα modulating agents currently licensed in the U.S. for treatinginflammatory conditions include Cimzia™ (certolizumab pegol), apegylated antibody fragment that binds to TNFα; Remicade™ (Infliximab),a chimeric antibody that binds TNFα; and Humira™ (adalimumab), ahumanized anti-TNFα antibody.

Celiac Disease

Celiac disease (CD) is a chronic autoimmune disease that is HLA-DQ2/DQ8haplotype restricted. Glutens, the major protein fraction of wheat, andrelated proteins in rye and barley are the triggering agents of thedisease. Ingested gluten or its derivative fractions (gliadin andsubunits) elicit a harmful T cell-mediated immune response aftercrossing the small bowel epithelial barrier, undergoing deamidation bytissue transglutaminase (tTG) and engaging class II MHC molecules.

While the earliest events leading to CD involve innate immune responses,evidence in the literature seems to suggest that a dysfunctional crosstalk between innate and adaptive immunity is also an importantpathogenic element in the autoimmune process of the disease. Underphysiological circumstances, the intestinal epithelium, with its intactintercellular tight junctions (tj), serves as a key barrier to thepassage of macromolecules such as gluten. When the integrity of the tjsystem is compromised, as in CD, a paracellular leak (“leaky gut”) andan inappropriate immune response to environmental antigens (i.e.,gluten) may develop.

In celiac intestinal tissues and in in vitro, ex vivo, and in vivoanimal experiments, gluten/gliadin causes a rapid increase inpermeability in normal and diseased states. Animal models likewise havedemonstrated the association of gluten, increased paracellularpermeability and other autoimmune diseases, including type 1 diabetes(T1 D).

AT-1001 is an orally administered octapeptide (Gly Gly Val Leu Val GlnPro Gly (SEQ ID NO:1), that appears to inhibit gliadin-induced TJdisassembly and prevent the associated increase in paracellularpermeability. Experiments with ex vivo human tissue and in micedemonstrate that AT-1001 blocks the peak of F-actin increment induced bygliadin and inhibits gliadin induced reduction in intestinal Rt(resistance).

There is a continuing need in the art for methods to treat inflammatoryand autoimmune diseases as well as diseases associated with biologicalbarrier dysfunction more effectively and to discover or identify drugswhich are suitable for treating inflammatory and autoimmune diseases aswell as diseases associated with biological barrier dysfunction.

SUMMARY OF THE INVENTION

One object of the present invention is to inhibit increased permeabilityof biological barriers in response to secreted signals.

Another object of the present invention is to provide compounds thatinhibit secretion of signals that cause increased permeability ofbiological barriers.

In particular embodiments the present invention provides compounds thatinhibit the secretion of signals that cause increased permeability ofbiological barriers, wherein the signals are secreted in response toexposure of lymphocytes to lipopolysaccharide (LPS). In other particularembodiments the present invention provides compounds that inhibit thesecretion of signals that cause increased permeability of biologicalbarriers, wherein the signals are secreted in response to exposure oflymphocytes to pepsin/trypsin treated gliadin (PTG).

Another object of the present invention is to provide pharmaceuticalcompositions that inhibit secretion of signals that cause increasedpermeability of biological barriers.

In particular embodiments the present invention provides pharmaceuticalcompositions that inhibit the secretion of signals that cause increasedpermeability of biological barriers, wherein the signals are secreted inresponse to exposure of lymphocytes to lipopolysaccharide (LPS). Inother particular embodiments the present invention providespharmaceutical compositions that inhibit the secretion of signals thatcause increased permeability of biological barriers, wherein the signalsare secreted in response to exposure of lymphocytes to pepsin/trypsintreated gliadin (PTG).

Another object of the present invention is to provide methods oftreating a patient showing an increased secretion of signals that causeincreased permeability of biological barriers.

In particular embodiments the present invention provides methods oftreating a patient showing an increased secretion of signals that causeincreased permeability of biological barriers, wherein the signals aresecreted in response to exposure of lymphocytes to lipopolysaccharide(LPS). In other particular embodiments the present invention providesmethods of treating a patient showing an increased secretion of signalsthat cause increased permeability of biological barriers, wherein thesignals are secreted in response to exposure of lymphocytes topepsin/trypsin treated gliadin (PTG).

In certain embodiments, the invention provides a method of treating apatient with an autoimmune or inflammation-associated disease. Thedisease is selected from the group consisting of inflammatory boweldisease, including Crohn's disease and ulcerative colitis, necrotizingenterocolitis, type 1 diabetes, celiac disease, autoimmune hepatitis,multiple sclerosis, autism, dermatitis herpetiformis, IgA nephropathy,primary biliary chirrosis, rheumatoid arthritis, systemic lupuserythematosus, Grave's disease, Hashimoto's disease, and depression. Acompound that inhibits the production, release and/or the biologicaleffects of TNFα is administered to the patient.

Another object of the present invention is to provide methods to inhibitparacellular passage of gluten derived peptides across an epithelialbarrier. Such methods comprise contacting the epithelial barrier withone or more peptide permeability inhibitors. Peptide permeabilityinhibitors for use in methods of the invention may comprise a peptide ofany length. Such peptide permeability inhibitors may comprise a peptidefrom three to ten amino acids in length. In some embodiments, a peptidepermeability inhibitor of the invention may comprise, consistessentially of, or consist of a peptide that comprises, consistsessentially of or consists of an amino acid sequence selected from thegroup consisting of SEQ ID NOs: 1-162. In some embodiments, a peptidepermeability inhibitor of the invention may comprise, consistessentially of, or consist of a peptide that comprises, consistsessentially of or consists of an amino acid sequence selected from thegroup consisting of SEQ ID NOs: 1-5, 10-17, 19-23, 27, 32, 34, 36, 48,49, 55, 58, 67-77, 79-85, 87, 88, 91, 92, 94, 98-104, 106, 110, 111,113-125, 127, 128, 147, 150, and 160-162. In some embodiments, theinvention does not include SEQ ID NOs: 15, 24, and 25.

The present invention also provides novel methods to inhibit increasedparacellular permeability associated with exposure of a biologicalbarrier to gluten derived peptides. Such methods comprise contacting theepithelial barrier with one or more peptide permeability inhibitors.Peptide permeability inhibitors for use in methods of the invention maycomprise a peptide of any length. Such peptide permeability inhibitorsmay comprise a peptide from three to ten amino acids in length. In someembodiments, a peptide permeability inhibitor of the invention maycomprise, consist essentially of, or consist of a peptide thatcomprises, consists essentially of or consists of an amino acid sequenceselected from the group consisting of SEQ ID NOs: 1-162. In someembodiments, a peptide permeability inhibitor of the invention maycomprise, consist essentially of, or consist of a peptide thatcomprises, consists essentially of or consists of an amino acid sequenceselected from the group consisting of of SEQ ID NOs: 1-5, 10-17, 19-23,27, 32, 34, 36, 48, 49, 55, 58, 67-77, 79-85, 87, 88, 91, 92, 94,98-104, 106, 110, 111, 113-125, 127, 128, 147, 150, and 160-162. In someembodiments, the invention does not include SEQ ID NOs: 15, 24, and 25.

The present invention also provides compositions, e.g., pharmaceuticalcompositions, comprising one or more peptide permeability inhibitors ofthe invention, useful to inhibit paracellular passage of gluten derivedpeptides across an epithelial barrier. Peptide permeability inhibitorsfor use in compositions of the invention may comprise a peptide of anylength. In some embodiments, such peptide permeability inhibitors maycomprise a peptide of between three to ten amino acids in length.Suitable peptide permeability inhibitors for use in the compositions ofthe invention include, but are not limited to, peptide permeabilityinhibitors that comprise, consist essentially of, or consist of an aminoacid sequence selected from the group consisting of SEQ ID NOs: 1-162.In some embodiments, peptide permeability inhibitors for use in thecompositions of the invention include, but are not limited to, peptidepermeability inhibitors comprising peptides that comprise, consistessentially of, or consist of an amino acid sequence selected from thegroup consisting of of SEQ ID NOs: 1-5, 10-17, 19-23, 27, 32, 34, 36,48, 49, 55, 58, 67-77, 79-85, 87, 88, 91, 92, 94, 98-104, 106, 110, 111,113-125, 127, 128, 147, 150, and 160-162. In some embodiments, theinvention does not include SEQ ID NOs: 15, 24, and 25.

Compositions of the invention, for example, pharmaceutical compositions,may be formulated for any type of delivery. For example, compositions ofthe invention may be formulated for intestinal delivery, e.g., may bedelayed release compositions. Compositions of the invention may also beformulated for pulmonary delivery, oral delivery and/or transcutaneousdelivery.

In one embodiment, the present invention provides a method of treating adisease in a subject in need thereof. Methods of the invention maycomprise administering to the subject a pharmaceutical compositioncomprising one or more peptide permeability inhibitors of the invention.Methods of the invention may comprise administering to the subject apharmaceutical composition comprising one or more peptide permeabilityinhibitors and one or more additional therapeutic agents. In oneembodiment, the present invention provides a method of treating celiacdisease in a subject in need thereof. In another embodiment, the presentinvention provides a method of treating necrotizing enterocolitis in asubject in need thereof. In another embodiment, the present inventionprovides a method of treating an excessive or undesirable immuneresponse in a subject in need thereof. In another embodiment, thepresent invention provides a method of treating inflammation in asubject in need thereof. In specific embodiments, the present inventionprovides methods of treating inflammatory bowel disease in a subject inneed thereof. Inflammatory bowel disease that can be treated usingmethods of the present invention may be Crohn's disease or ulcerativecolitis.

In further embodiments the invention provides methods of treating anautoimmune or inflammation-associated disease in a patient in need ofsuch treatment. The disease is selected from the group consisting oftype 1 diabetes, celiac disease, autoimmune hepatitis, multiplesclerosis, autism, dermatitis herpetiformis, IgA nephropathy, primarybiliary chirrosis, rheumatoid arthritis, systemic lupus erythematosus,Grave's disease, Hashimoto's disease, and depression.

The foregoing has outlined rather broadly the features and technicaladvantages of the present invention in order that the detaileddescription of the invention that follows may be better understood.Additional features and advantages of the invention will be describedherein, which form the subject of the claims of the invention. It shouldbe appreciated by those skilled in the art that any conception andspecific embodiment disclosed herein may be readily utilized as a basisfor modifying or designing other structures for carrying out the samepurposes of the present invention. It should also be realized by thoseskilled in the art that such equivalent constructions do not depart fromthe spirit and scope of the invention as set forth in the appendedclaims. The novel features which are believed to be characteristic ofthe invention, both as to its organization and method of operation,together with further objects and advantages will be better understoodfrom the following description when considered in connection with theaccompanying figures. It is to be expressly understood, however, thatany description, figure, example, etc. is provided for the purpose ofillustration and description only and is by no means intended to definethe limits the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic representation of the events leading to Celiacdisease pathology. Gliadin fragments cross the intestinal epithelium andactivate immune cells to produce soluble factors including cytokinesthat lead to increased permeability of the intestinal epithelium.

FIG. 2 is a schematic representation of the blockade of the gliadinfragment entry, the initial step leading to Celiac disease pathology.Gliadin fragments cross the intestinal epithelium and activate immunecells to produce soluble factors including cytokines that lead toincreased permeability of the intestinal epithelium.

FIG. 3 shows the effect of a peptide permeability inhibitor (SEQ IDNO:1) on permeability of a CaCO2 cell monolayer to a gliadin fragment.Apical exposure of the monolayer to the gliadin peptide PYPQPQLPY (SEQID NO:163) lead to an increase in permeability to that peptide, whichcould be blocked by apical treatment with a peptide permeabilityinhibitor (SEQ ID NO:1).

FIG. 4 shows the effect of a 13-mer gliadin peptide (LGQQQPFPPQQPY; SEQID NO:164) on permeability of a CaCO2 cell monolayer induced by a.Apical exposure of the monolayer to the gliadin peptideFITC-C6-PYPQPQLPY lead to an increase in permeability that could beblocked by treatment with a peptide permeability inhibitor (SEQ IDNO:1).

FIG. 5A shows the effects on CaCO2 cell permeability of 72 hourstreatment with peptide permeability inhibitor (SEQ ID NO:1) incombination with culture supernatants prepared from donor PBMCs (00022).After formation of tight junctions CaCO2 cells were exposedbasolaterally to control supernatant (control), untreated PBMCsupernatant (PBMC sup), LPS treated PBMC supernatant (PBMC-LPS) and PTGtreated PBMC supernatant (PBMC-PTG). Lucifer yellow permeability wasmeasured after 72 hours (day3). Simultaneous apical addition of peptidepermeability inhibitor (SEQ ID NO:1) on day 0 abolished baselinepermeability to Lucifer yellow (control+AT-1001; and PBMC sup+AT1001)but had no significant effect on permeability changes induced by LPS(PBMC-LPS+AT1001) or PTG treated PBMC supernatant (PBMC-PTG+AT1001).

FIG. 5B shows the effects on CaCO2 cell permeability of 72 hoursexposure to culture supernatants prepared from donor PBMCs (00022)followed by addition of peptide permeability inhibitor (SEQ ID NO:1)after 48 hours treatment. After formation of tight junctions CaCO2 cellswere exposed basolaterally to PBMC supernatants as described above.Peptide permeability inhibitor (SEQ ID NO:1) was added apically to thecultures after 48 hours (day 2), and lucifer yellow permeability wasmeasured after 72 hours (day3). Apical addition of peptide permeabilityinhibitor (SEQ ID NO:1) on day 2 abolished baseline permeability toLucifer yellow (control+AT-1001; and PBMC sup+AT1001), and itsignificantly reduced permeability changes induced by LPS(PBMC-LPS+AT1001) or PTG treated PBMC supernatant (PBMC-PTG+AT1001).

FIG. 6A shows the effects on CaCO2 cell permeability of 72 hourstreatment with peptide permeability inhibitor (SEQ ID NO:1) incombination with culture supernatants prepared from donor PBMCs (00023).After formation of tight junctions CaCO2 cells were exposedbasolaterally to control supernatant (control), untreated PBMCsupernatant (PBMC sup), LPS treated PBMC supernatant (PBMC-LPS) and PTGtreated PBMC supernatant (PBMC-PTG). Lucifer yellow permeability wasmeasured after 72 hours (day3). Simultaneous apical addition of peptidepermeability inhibitor (SEQ ID NO:1) on day 0 abolished baselinepermeability to Lucifer yellow (control+AT-1001; and PBMC sup+AT1001)but had no significant effect on permeability changes induced by LPS(PBMC-LPS+AT1001) or PTG treated PBMC supernatant (PBMC-PTG+AT1001).

FIG. 6B shows the effects on CaCO2 cell permeability of 72 hoursexposure to culture supernatants prepared from donor PBMCs (00023)followed by addition of peptide permeability inhibitor (SEQ ID NO:1)after 48 hours treatment. After formation of tight junctions CaCO2 cellswere exposed basolaterally to PBMC supernatants as described above.Peptide permeability inhibitor (SEQ ID NO:1) was added apically to thecultures after 48 hours (day 2), and lucifer yellow permeability wasmeasured after 72 hours (day3). Apical addition of peptide permeabilityinhibitor (SEQ ID NO:1) on day 2 abolished baseline permeability toLucifer yellow (control+AT-1001; and PBMC sup+AT1001), and itsignificantly reduced permeability changes induced by LPS(PBMC-LPS+AT1001) or PTG treated PBMC supernatant (PBMC-PTG+AT1001).

FIG. 7A shows the effects on CaCO2 cell permeability of 72 hourstreatment with peptide permeability inhibitor (SEQ ID NO:1) incombination with culture supernatants prepared from donor PBMCs (00064).After formation of tight junctions CaCO2 cells were exposedbasolaterally to control supernatant (control), untreated PBMCsupernatant (PBMC sup), LPS treated PBMC supernatant (PBMC-LPS) and PTGtreated PBMC supernatant (PBMC-PTG). Lucifer yellow permeability wasmeasured after 72 hours (day3). Simultaneous apical addition of peptidepermeability inhibitor (SEQ ID NO:1) on day 0 abolished baselinepermeability to Lucifer yellow (control+AT-1001; and PBMC sup+AT1001)but had no significant effect on permeability changes induced by LPS(PBMC-LPS+AT1001) or PTG treated PBMC supernatant (PBMC-PTG+AT1001).

FIG. 7B shows the effects on CaCO2 cell permeability of 72 hoursexposure to culture supernatants prepared from donor PBMCs (00064)followed by addition of peptide permeability inhibitor (SEQ ID NO:1)after 48 hours treatment. After formation of tight junctions CaCO2 cellswere exposed basolaterally to PBMC supernatants as described above.Peptide permeability inhibitor (SEQ ID NO:1) was added apically to thecultures after 48 hours (day 2), and lucifer yellow permeability wasmeasured after 72 hours (day3). Apical addition of peptide permeabilityinhibitor (SEQ ID NO:1) on day 2 abolished baseline permeability toLucifer yellow (control+AT-1001; and PBMC sup+AT1001), and itsignificantly reduced permeability changes induced by LPS(PBMC-LPS+AT1001) or PTG treated PBMC supernatant (PBMC-PTG+AT1001).

FIG. 8A shows the effects on CaCO2 cell permeability of 72 hourstreatment with peptide permeability inhibitor (SEQ ID NO:1) incombination with culture supernatants prepared from donor PBMCs (00065).After formation of tight junctions CaCO2 cells were exposedbasolaterally to control supernatant (control), untreated PBMCsupernatant (PBMC sup), LPS treated PBMC supernatant (PBMC-LPS) and PTGtreated PBMC supernatant (PBMC-PTG). Lucifer yellow permeability wasmeasured after 72 hours (day3). Simultaneous apical addition of peptidepermeability inhibitor (SEQ ID NO:1) on day 0 abolished baselinepermeability to Lucifer yellow (control+AT-1001; and PBMC sup+AT1001)but had no significant effect on permeability changes induced by LPS(PBMC-LPS+AT1001) or PTG treated PBMC supernatant (PBMC-PTG+AT1001).

FIG. 8B shows the effects on CaCO2 cell permeability of 72 hoursexposure to culture supernatants prepared from donor PBMCs (00065)followed by addition of peptide permeability inhibitor (SEQ ID NO:1)after 48 hours treatment. After formation of tight junctions CaCO2 cellswere exposed basolaterally to PBMC supernatants as described above.Peptide permeability inhibitor (SEQ ID NO:1) was added apically to thecultures after 48 hours (day 2), and lucifer yellow permeability wasmeasured after 72 hours (day3). Apical addition of peptide permeabilityinhibitor (SEQ ID NO:1) on day 2 abolished baseline permeability toLucifer yellow (control+AT-1001; and PBMC sup+AT1001), and itsignificantly reduced permeability changes induced by LPS(PBMC-LPS+AT1001) or PTG treated PBMC supernatant (PBMC-PTG+AT1001).

DETAILED DESCRIPTION OF THE INVENTION

The inventors have discovered that peripheral blood mononuclear cells(PBMCs) secrete signals that increase epithelial monolayer permeabilityon response to stimulation with lipopolysaccharide (PLPS) andpepsin/trypsin treated gliadin (PTG). These secreted signals are presentin PBMC culture supernatant, and they increase permeability of CaCO2cell monolayers to Lucifer yellow when presented to the basolateralaspect of these cells. These permeability changes are inhibited bytreatment of the cells with peptide permeability inhibitors of theinvention (FIGS. 5A, 5B, 6A, 6B, 7A, 7B, 8A and 8B). The inventors havealso discovered that specific peptides within the PTG mixture arecapable of crossing epithelial cell monolayers in vitro, and that thispeptide specific mechanism can be inhibited by peptide permeabilityinhibitors of the invention (FIGS. 3 and 4).

DEFINITIONS

Unless otherwise noted, technical terms are used according toconventional usage. Definitions of common terms in molecular biology maybe found, for example, in Benjamin Lewin, Genes VII, published by OxfordUniversity Press, 2000 (ISBN 019879276X); Kendrew et al. (eds.); TheEncyclopedia of Molecular Biology, published by Blacicwell Publishers,1994 (ISBN 0632021829); and Robert A. Meyers (ed.), Molecular Biologyand Biotechnology: a Comprehensive Desk Reference, published by Wiley,John & Sons, Inc., 1995 (ISBN 0471186341); and other similar technicalreferences.

As used herein, “a” or “an” may mean one or more. As used herein in theclaim(s), when used in conjunction with the word “comprising”, the words“a” or “an” may mean one or more than one. As used herein “another” maymean at least a second or more. Furthermore, unless otherwise requiredby context, singular terms shall include pluralities and plural termsshall include the singular.

As used herein, “biological effect” refers to a biochemical andphysiological effect. Biological effect includes, for example, increasesor decreases in the activity of the immune system and any of itscomponents (including, for example, complement activation), increases ordecreases in receptor binding and increases or decreases in subsequentdownstream effector cellular constituents (including, for example,growth factor receptor and downstream effector cellular constituents),increases or decreases in cell signaling, increases or decreases in geneexpression, increases or decreased in post-translation modification ofproteins (including, for example, phosphorylation), and increases ordecreases in protein activity.

As used herein, “modulate” and all its forms and tenses refer to eitherincreasing or decreasing a particular biochemical or physiologicaleffect.

As used herein, A “component of the immune system” or an “immune cell”refers to a component or cell of the immune system that is involved inenhancing, eliciting, or maintaining an immune response. The immunesystem responds to various foreign particles (including, for example,viruses, bacteria, and allergens) and non-foreign particles (including,for example, native endogenous proteins). An immune response includes,for example, antibody production, chemotaxis, phagocytosis,inflammation, complement activation, production of cytotoxic molecules(including, for example, reactive oxygen species and reactive nitrogenspecies), cell adhesion, cell infiltration, and production andrecruitment of mediators of any of the foregoing or other immuneresponses. A component or cell of the immune system involved inenhancing, eliciting, or maintaining an immune response includes, forexample, neutrophils, complement proteins (including, for example, Clq,Clr and Cls), eosinophils, basophils, lymphocytes (including forexample, T cells (including, for example, cytotoxic T cells, memory Tcells, helper T cells, regulatory T cells, natural killer T cells, andγδ T cells) and B cells (including, for example, plasma B cells, memoryB cells, B-1 cells, and B-2 cells)), monocytes, macrophages, dendriticcells (DC), cell adhesion molecules (including, for example, ICAM andVCAM), myeloperoxidase, nitric oxide synthase, cyclooxygenase, andprostaglandin synthase.

As used herein, “treat” and all its forms and tenses refer to boththerapeutic treatment and prophylactic or preventative treatment. Thosein need of treatment include those already with the condition or diseaseas well as those in which the condition or disease is to be prevented.

Present Invention

The inventors have identified novel methods and compounds that inhibitincreased permeability of biological barriers in response to stimulithat are known to induce secretion of pro-inflammatory cytokines. Inspecific embodiments the inventors have identified methods and compoundsthat inhibit increased permeability of biological barriers afterstimulation by factors secreted by immune cells on exposure to LPS. Infurther specific embodiments the inventors have identified methods andcompounds that inhibit increased permeability of biological barriersafter stimulation by factors secreted by immune cells on exposure toPTG. Exemplary compounds of the invention that inhibit increasedpermeability of biological barriers are presented in Table 20.

The inventors have also identified novel methods and compounds thatinhibit, reduce and/or prevent translocation of PTG-derived peptidesacross biological barriers. In specific embodiments the inventors haveidentified methods and compounds that inhibit, reduce and/or preventtranslocation of the peptide comprising the amino acid sequencePYPQPQLPY (SEQ ID NO:163). Exemplary compounds of the invention thatinhibit, reduce and/or prevent translocation of PTG-derived peptidesacross biological barriers are presented in Table 20.

Inhibitors of biological barrier permeability may be used in thepractice of the present invention. Such permeability inhibitors may alsobe antagonists of mammalian tight junction opening. Antagonists ofmammalian tight junction opening may also be used in the practice of thepresent invention. As used herein, permeability inhibitors prevent,inhibit or reduce the permeability of biological barriers tomacromolecules including, for example, proteins, peptides and nucleicacids. For example, permeability inhibitors of the invention maycomprise peptide permeability inhibitors. Examples of peptidepermeability inhibitors that may be used in the practice of the presentinvention include, but are not limited to, peptides that comprise anamino acid sequence selected from the group consisting of: consist of anamino acid sequence selected from the group consisting of SEQ ID NOs:1-5, 10-17, 19-23, 27, 32, 34, 36, 48, 49, 55, 58, 67-77, 79-85, 87, 88,91, 92, 94, 98-104, 106, 110, 111, 113-125, 127, 128, 147, 150, and160-162.

Examples of peptide permeability inhibitors include, but are not limitedto, peptides that consist of an amino acid sequence selected from thegroup consisting of SEQ ID NOs:1-162.

When the permeability inhibitor is a peptide, any length of peptide maybe used. Generally, the size of the peptide antagonist will range fromabout 6 to about 100, from about 6 to about 90, from about 6 to about80, from about 6 to about 70, from about 6 to about 60, from about 6 toabout 50, from about 6 to about 40, from about 6 to about 30, from about6 to about 25, from about 6 to about 20, from about 6 to about 15, fromabout 6 to about 14, from about 6 to about 13, from about 6 to about 12,from about 6 to about 11, from about 6 to about 10, from about 6 toabout 9, or from about 6 to about 8 amino acids in length. Peptideantagonists of the invention may be from about 8 to about 100, fromabout 8 to about 90, from about 8 to about 80, from about 8 to about 70,from about 8 to about 60, from about 8 to about 50, from about 8 toabout 40, from about 8 to about 30, from about 8 to about 25, from about8 to about 20, from about 8 to about 15, from about 8 to about 14, fromabout 8 to about 13, from about 8 to about 12, from about 8 to about 11,or from about 8 to about 10 amino acids in length. Peptide antagonistsof the invention may be from about 10 to about 100, from about 10 toabout 90, from about 10 to about 80, from about 10 to about 70, fromabout 10 to about 60, from about 10 to about 50, from about 10 to about40, from about 10 to about 30, from about 10 to about 25, from about 10to about 20, from about 10 to about 15, from about 10 to about 14, fromabout 10 to about 13, or from about 10 to about 12 amino acids inlength. Peptide antagonists of the invention may be from about 12 toabout 100, from about 12 to about 90, from about 12 to about 80, fromabout 12 to about 70, from about 12 to about 60, from about 12 to about50, from about 12 to about 40, from about 12 to about 30, from about 12to about 25, from about 12 to about 20, from about 12 to about 15, orfrom about 12 to about 14 amino acids in length. Peptide antagonists ofthe invention may be from about 15 to about 100, from about 15 to about90, from about 15 to about 80, from about 15 to about 70, from about 15to about 60, from about 15 to about 50, from about 15 to about 40, fromabout 15 to about 30, from about 15 to about 25, from about 15 to about20, from about 19 to about 15, from about 15 to about 18, or from about17 to about 15 amino acids in length.

The peptide permeability inhibitors can be chemically synthesized andpurified using well-known techniques, such as described in HighPerformance Liquid Chromatography of Peptides and Proteins: SeparationAnalysis and Conformation, Eds. Mant et al., C.R.C. Press (1991), and apeptide synthesizer, such as Symphony (Protein Technologies, Inc); or byusing recombinant DNA techniques, i.e., where the nucleotide sequenceencoding the peptide is inserted in an appropriate expression vector,e.g., an E. coli or yeast expression vector, expressed in the respectivehost cell, and purified therefrom using well-known techniques.

Compositions

Typically, compositions, such as pharmaceutical compositions, compriseone or more compounds of the invention, and optionally one or moreadditional active agents. Compounds of the invention may be present inan amount sufficient to inhibit the increased biological barrierpermeability in a subject in need thereof. Compounds of the inventionmay be present in an amount sufficient to inhibit, reduce and/or preventtranslocation of a gliadin-derived peptide across a biological barrierin a subject in need thereof. The amount of a compound of the inventionemployed in any given composition may vary according to factors such asthe disease state, age, sex, and weight of the subject. Dosage regimensmay be adjusted to provide the optimum therapeutic response. Forexample, a single bolus may be administered, several divided doses maybe administered over time or the dose may be proportionally reduced orincreased as indicated by the exigencies of the therapeutic situation.

Generally, a pharmaceutical composition of the invention will comprisean amount of a compound of the invention in the range of about 1 μg toabout 1 g, preferably about 1 mg to about 1000 mg, from about 10 mg toabout 100 mg, from about 10 mg to about 50 mg, or from about 10 mg toabout 25 mg of the compound. As used herein, “about” used to modify anumerical value means within 10% of the value.

Compositions of the invention may comprise one or more compounds of theinvention at a level of from about 0.1 wt % to about 20 wt %, from about0.1 wt % to about 18 wt %, from about 0.1 wt % to about 16 wt %, fromabout 0.1 wt % to about 14 wt %, from about 0.1 wt % to about 12 wt %,from about 0.1 wt % to about 10 wt %, from about 0.1 wt % to about 8 wt%, from about 0.1 wt % to about 6 wt %, from about 0.1 wt % to about 4wt %, from about 0.1 wt % to about 2 wt %, from about 0.1 wt % to about1 wt %, from about 0.1 wt % to about 0.9 wt %, from about 0.1 wt % toabout 0.8 wt %, from about 0.1 wt % to about 0.7 wt %, from about 0.1 wt% to about 0.6 wt %, from about 0.1 wt % to about 0.5 wt %, from about0.1 wt % to about 0.4 wt %, from about 0.1 wt % to about 0.3 wt %, orfrom about 0.1 wt % to about 0.2 wt % of the total weight of thecomposition. As used herein, “about” used to modify a numerical valuemeans within 10% of the value. Compositions of the invention maycomprise one or more compounds of the invention at a level of about 0.1wt %, about 0.2 wt %, about 0.3 wt %, about 0.4 wt %, about 0.5 wt %,about 0.6 wt %, about 0.7 wt %, about 0.8 wt %, or about 0.9 wt % basedon the total weight of the composition.

Compositions of the invention may comprise one or more compounds of theinvention at a level of from about 1 wt % to about 20 wt %, from about 1wt % to about 18 wt %, from about 1 wt % to about 16 wt %, from about 1wt % to about 14 wt %, from about 1 wt % to about 12 wt %, from about 1wt % to about 10 wt %, from about 1 wt % to about 9 wt %, from about 1wt % to about 8 wt %, from about 1 wt % to about 7 wt %, from about 1 wt% to about 6 wt %, from about 1 wt % to about 5 wt %, from about 1 wt %to about 4 wt %, from about 1 wt % to about 3 wt %, or from about 1 wt %to about 2 wt % of the total weight of the composition. As used herein,“about” used to modify a numerical value means within 10% of the value.Compositions of the invention may comprise one or more compounds of theinvention at a level of about 1 wt %, about 2 wt %, about 3 wt %, about4 wt %, about 5 wt %, about 6 wt %, about 7 wt %, about 8 wt %, or about9 wt % based on the total weight of the composition.

Compositions of the invention, for example, pharmaceutical compositionscomprising one or more compounds of the invention and one or moreadditional active agents, may be formulated for pulmonary delivery(e.g., may be pulmonary dosage forms). Typically such compositions maybe provided as pharmaceutical aerosols, e.g., solution aerosols orpowder aerosols. Those of skill in the art are aware of many differentmethods and devices for the formation of pharmaceutical aerosols, forexample, those disclosed by Sciarra and Sciarra, Aerosols, in Remington:The Science and Practice of Pharmacy, 20th Ed., Chapter 50, Gennaro etal. Eds., Lippincott, Williams and Wilkins Publishing Co., (2000).

In one embodiment, the dosage forms are in the form of a powder aerosol(i.e, comprise particles). These are particularly suitable for use ininhalation delivery systems. Powders may comprise particles of any sizesuitable for administration to the lung.

Powder formulations may optionally contain at least one particulatepharmaceutically acceptable carrier known to those of skill in the art.Examples of suitable pharmaceutical carriers include, but are notlimited to, saccharides, including monosaccharides, disaccharides,polysaccharides and sugar alcohols such as arabinose, glucose, fructose,ribose, mannose, sucrose, trehalose, lactose, maltose, starches,dextran, mannitol or sorbitol. In one embodiment, a powder formulationmay comprise lactose as a carrier.

Powder formulations may be contained in any container known to those inthe art. Containers may be capsules of, for example, gelatin or plastic,or in blisters (e.g. of aluminum or plastic), for use in a dry powderinhalation device. In some embodiments, the total weight of theformulation in the container may be from about 5 mg to about 50 mg. Inother embodiments, powder formulations may be contained in a reservoirin a multi-dose dry powder inhalation device adapted to deliver asuitable amount per actuation.

Powder formulations typically comprise small particles. Suitableparticles can be prepared using any means known in the art, for example,by grinding in an airjet mill, ball mill or vibrator mill, sieving,microprecipitation, spray-drying, lyophilisation or controlledcrystallisation. Typically, particles will be about 10 microns or lessin diameter. Particles for use in the compositions of the invention mayhave a diameter of from about 0.1 microns to about 10 microns, fromabout 0.1 microns to about 9 microns, from about 0.1 microns to about 8microns, from about 0.1 microns to about 7 microns, from about 0.1microns to about 6 microns, from about 0.1 microns to about 5 microns,from about 0.1 microns to about 4 microns, from about 0.1 microns toabout 3 microns, from about 0.1 microns to about 2 microns, from about0.1 microns to about 1 micron, from about 0.1 microns to about 0.5microns, from about 1 micron to about 10 microns, from about 1 micron toabout 9 microns, from about 1 micron to about 8 microns, from about 1micron to about 7 microns, from about 1 micron to about 6 microns, fromabout 1 micron to about 5 microns, from about 1 micron to about 4microns, from about 1 micron to about 3 microns, from about 1 micron toabout 2 microns, from about 2 microns to about 10 microns, from about 2microns to about 9 microns, from about 2 microns to about 8 microns,from about 2 microns to about 7 microns, from about 2 microns to about 6microns, from about 2 microns to about 5 microns, from about 2 micronsto about 4 microns, or from about 2 microns to about 3 microns. As usedherein, “about” used to modify a numerical value means within 10% of thevalue. In some embodiments, particles for use in the invention may beabout 1 micron, about 2 microns, about 3 microns, about 4 microns, about5 microns, about 6 microns, about 7 microns, about 8 microns, about 9microns, or about 10 microns in diameter.

In one embodiment, the dosage forms are in the form of a solutionaerosol (i.e., comprise droplets). Typically, droplets will be about 10microns or less in diameter. Droplets for use in the compositions of theinvention may have a diameter of from about 0.1 microns to about 10microns, from about 0.1 microns to about 9 microns, from about 0.1microns to about 8 microns, from about 0.1 microns to about 7 microns,from about 0.1 microns to about 6 microns, from about 0.1 microns toabout 5 microns, from about 0.1 microns to about 4 microns, from about0.1 microns to about 3 microns, from about 0.1 microns to about 2microns, from about 0.1 microns to about 1 micron, from about 0.1microns to about 0.5 microns, from about micron to about 10 microns,from about 1 micron to about 9 microns, from about 1 micron to about 8microns, from about 1 micron to about 7 microns, from about 1 micron toabout 6 microns, from about 1 micron to about 5 microns, from about 1micron to about 4 microns, from about 1 micron to about 3 microns, fromabout 1 micron to about 2 microns, from about 2 microns to about 10microns, from about 2 microns to about 9 microns, from about 2 micronsto about 8 microns, from about 2 microns to about 7 microns, from about2 microns to about 6 microns, from about 2 microns to about 5 microns,from about 2 microns to about 4 microns, or from about 2 microns toabout 3 microns. As used herein, “about” used to modify a numericalvalue means within 10% of the value. In some embodiments, particlesand/or droplets for use in the invention may be about 1 micron, about 2microns, about 3 microns, about 4 microns, about 5 microns, about 6microns, about 7 microns, about 8 microns, about 9 microns, or about 10microns in diameter.

The compositions of the invention may be formulated for entericdelivery, for example, may comprise one or more coatings including, forexample, a delayed release coating containing one or more entericagents. A delayed release coating is typically substantially stable ingastric fluid and substantially unstable (e.g., dissolves rapidly or isphysically unstable) in intestinal fluid, thus providing for substantialrelease of the compounds of the invention and/or additional active agentfrom the composition in the duodenum or the jejunum.

The term “stable in gastric fluid” refers to a composition that releases30% or less by weight of the total compound of the invention and/oradditional active agent in the composition in gastric fluid with a pH of5 or less, or simulated gastric fluid with a pH of 5 or less, inapproximately sixty minutes. Examples of simulated gastric fluid andsimulated intestinal fluid include, but are not limited to, thosedisclosed in the 2005 Pharmacopeia 23NF/28USP in Test Solutions at page2858 and/or other simulated gastric fluids and simulated intestinalfluids known to those of skill in the art, for example, simulatedgastric fluid and/or intestinal fluid prepared without enzymes.

Compositions of the of the invention may release from about 0% to about30%, from about 0% to about 25%, from about 0% to about 20%, from about0% to about 15%, from about 0% to about 10%, from about 5% to about 30%,from about 5% to about 25%, from about 5% to about 20%, from about 5% toabout 15%, from about 5% to about 10% by weight of the total compound ofthe invention and/or additional active agent in the composition ingastric fluid with a pH of 5 or less, or simulated gastric fluid with apH of 5 or less, in approximately sixty minutes. As used herein, “about”used to modify a numerical value means within 10% of the value.Compositions of the invention may release about 1%, about 2%, about 3%,about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%by weight of the total compound of the invention in the composition ingastric fluid with a pH of 5 or less, or simulated gastric fluid with apH of 5 or less, in approximately sixty minutes.

The term “unstable in intestinal fluid” refers to a composition thatreleases 70% or more by weight of the total amount of the compound ofthe invention and/or additional active agent in the composition inintestinal fluid or simulated intestinal fluid in approximately sixtyminutes. The term “unstable in near neutral to alkaline environments”refers to a composition that releases 70% or more by weight of the totalamount of the compound of the invention and/or additional active agentin the composition in intestinal fluid with a pH of 5 or greater, orsimulated intestinal fluid with a pH of 5 or greater, in approximatelyninety minutes. For example, a composition that is unstable in nearneutral or alkaline environments may release 70% or more by weight of acompound of the invention and/or additional active agent in a fluidhaving a pH greater than about 5 (e.g., a fluid having a pH of fromabout 5 to about 14, from about 6 to about 14, from about 7 to about 14,from about 8 to about 14, from about 9 to about 14, from about 10 toabout 14, or from about 11 to about 14) in from about 5 minutes to about90 minutes, from about 10 minutes to about 90 minutes, from about 15minutes to about 90 minutes, from about 20 minutes to about 90 minutes,from about 25 minutes to about 90 minutes, from about 30 minutes toabout 90 minutes, from about 5 minutes to about 60 minutes, from about10 minutes to about 60 minutes, from about 15 minutes to about 60minutes, from about 20 minutes to about 60 minutes, from about 25minutes to about 60 minutes, or from about 30 minutes to about 60minutes. As used herein, “about” used to modify a numerical value meanswithin 10% of the value.

Compositions of the invention may be formulated for transcutaneousdelivery (e.g., may be transcutaneous dosage forms). Typically suchcompositions may be provided as topical solutions and/or gels. Those ofskill in the art are aware of many different methods and devices for theformation of topical medications, for example, those disclosed by Block,Medicated Topicals, in Remington: The Science and Practice of Pharmacy,20th Ed., Chapter 44, Gennaro et al. Eds., Lippincott, Williams andWilkins Publishing Co. (2000).

Various delivery systems are known and can be used to administer acompound of the invention, e.g., encapsulation in liposomes,microparticles, microcapsules, recombinant cells capable of expressingthe compound, receptor-mediated endocytosis etc. Methods of introductioninclude but are not limited to intradermal, intramuscular,intraperitoneal, intravenous, subcutaneous, intranasal, epidural, andoral routes. The compounds or compositions may be administered by anyconvenient route, for example by infusion or bolus injection, byabsorption through epithelial or mucocutaneous linings (e.g., oralmucosa, rectal and intestinal mucosa, etc.) and may be administeredtogether with other biologically active agents. Administration can besystemic or local. In addition, it may be desirable to introduce thepharmaceutical compounds or compositions of the invention into thecentral nervous system by any suitable route, including intraventricularand intrathecal injection; intraventricular injection may be facilitatedby an intraventricular catheter, for example, attached to a reservoir,such as an Ommaya reservoir. Pulmonary administration can also beemployed, e.g., by use of an inhaler or nebulizer, and formulation withan aerosolizing agent.

In a specific embodiment, it may be desirable to administer thepharmaceutical compounds or compositions of the invention locally to thearea in need of treatment; this may be achieved by, for example, and notby way of limitation, local infusion during surgery, topicalapplication, e.g., in conjunction with a wound dressing after surgery,by injection, by means of a catheter, by means of a suppository, or bymeans of an implant, said implant being of a porous, non-porous, orgelatinous material, including membranes, such as sialastic membranes,or fibers. Preferably, when administering a protein, including anantibody, of the invention, care must be taken to use materials to whichthe protein does not adsorb.

In another embodiment, the compound or composition can be delivered in avesicle, in particular a liposome.

In yet another embodiment, the compound or composition can be deliveredin a controlled release system. In one embodiment, a pump may be used.In another embodiment, polymeric materials can be used. In yet anotherembodiment, a controlled release system can be placed in proximity ofthe therapeutic target, i.e., the brain, thus requiring only a fractionof the systemic dose. Other controlled release systems are well known inthe art.

The present invention also provides pharmaceutical compositions. Suchcompositions comprise a therapeutically effective amount of a compound,and a pharmaceutically acceptable carrier. In a specific embodiment, theterm “pharmaceutically acceptable” means approved by a regulatory agencyof the Federal or a state government or listed in the U.S. Pharmacopeiaor other generally recognized pharmacopeia for use in animals, and moreparticularly in humans. The term “carrier” refers to a diluent,adjuvant, excipient, or vehicle with which the therapeutic isadministered. Such pharmaceutical carriers can be sterile liquids, suchas water and oils, including those of petroleum, animal, vegetable orsynthetic origin, such as peanut oil, soybean oil, mineral oil, sesameoil and the like. Water is a preferred carrier when the pharmaceuticalcomposition is administered intravenously. Saline solutions and aqueousdextrose and glycerol solutions can also be employed as liquid carriers,particularly for injectable solutions. Suitable pharmaceuticalexcipients include starch, glucose, lactose, sucrose, gelatin, malt,rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate,talc, sodium chloride, dried skim milk, glycerol, propylene, glycol,water, ethanol and the like. The composition, if desired, can alsocontain minor amounts of wetting or emulsifying agents, or pH bufferingagents. These compositions can take the form of solutions, suspensions,emulsion, tablets, pills, capsules, powders, sustained-releaseformulations and the like. The composition can be formulated as asuppository, with traditional binders and carriers such astriglycerides. Oral formulation can include standard carriers such aspharmaceutical grades of mannitol, lactose, starch, magnesium stearate,sodium saccharine, cellulose, magnesium carbonate, etc. Examples ofsuitable pharmaceutical carriers are described in “Remington'sPharmaceutical Sciences” by E. W. Martin. Such compositions will containa therapeutically effective amount of the compound, preferably inpurified form, together with a suitable amount of carrier so as toprovide the form for proper administration to the patient. Theformulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordancewith routine procedures as a pharmaceutical composition adapted forintravenous administration to human beings. Typically, compositions forintravenous administration are solutions in sterile isotonic aqueousbuffer. Where necessary, the composition may also include a solubilizingagent and a local anesthetic such as lignocaine to ease pain at the siteof the injection. Generally, the ingredients are supplied eitherseparately or mixed together in unit dosage form, for example, as a drylyophilized powder or water free concentrate in a hermetically sealedcontainer such as an ampoule or sachette indicating the quantity ofactive agent. Where the composition is to be administered by infusion,it can be dispensed with an infusion bottle containing sterilepharmaceutical grade water or saline. Where the composition isadministered by injection, an ampoule of sterile water for injection orsaline can be provided so that the ingredients may be mixed prior toadministration.

The compounds of the invention can be formulated as neutral or saltforms. Pharmaceutically acceptable salts include those formed withanions such as those derived from hydrochloric, phosphoric, acetic,oxalic, tartaric acids, etc., and those formed with cations such asthose derived from sodium, potassium, ammonium, calcium, ferrichydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol,histidine, procaine, etc.

The amount of the compound of the invention that will be effective inthe treatment, inhibition and/or prevention of a disease or disorderassociated with increased biological barrier permeability can bedetermined by standard clinical techniques. The amount of the compoundof the invention that will be effective in the treatment, inhibitionand/or prevention of a disease or disorder associated with translocationof one or more gliadin-derived peptides across a biological barrier canbe determined by standard clinical techniques. In addition, in vitroassays may optionally be employed to help identify optimal dosageranges. The precise dose to be employed in the formulation will alsodepend on the route of administration, and the seriousness of thedisease or disorder, and should be decided according to the judgment ofthe practitioner and each patient's circumstances. Effective doses maybe extrapolated from dose-response curves derived from in vitro oranimal model test systems.

The invention also provides a pharmaceutical pack or kit comprising oneor more containers filled with one or more of the ingredients of thepharmaceutical compositions of the invention. Optionally associated withsuch container(s) can be a notice in the form prescribed by agovernmental agency regulating the manufacture, use or sale ofpharmaceuticals or biological products, which notice reflects approvalby the agency of manufacture, use or sale for human administration.

Additional Active Agents

In addition to one or more compounds of the invention, compositions ofthe invention may further comprise one or more additional active agents,e.g., therapeutic agents, immunogenic agents and/or imaging agents.

Additional therapeutic agents that can be used in the compositions ofthe invention include agents that act on any organ of the body, such asheart, brain, intestine, or kidneys. Suitable additional therapeuticagents include, but are not limited to, glucose metabolism agents (e.g.,insulin), antibiotics, antineoplastics, antihypertensives,antiepileptics, central nervous system agents, anti-inflammatory agentsand immune system suppressants.

Additional therapeutic agents that can be used in the compositions ofthe invention include immunosuppressive agents. Such immunosuppressantsused in the method and composition of the invention can be any agentwhich tends to attenuate the activity of the humoral or cellular immunesystems. In particular, in one aspect the invention comprisescompositions wherein the immunosuppressant is selected from the groupconsisting of cyclosporin A, FK506, prednisone, methylprednisolone,cyclophosphamide, thalidomide, azathioprine, and daclizumab, physalin B,physalin F, physalin G, seco-steroids purified from Physalis angulataL., 15-deoxyspergualin (DSG, 15-dos), MMF, rapamycin and itsderivatives, CCI-779, FR 900520, FR 900523, NK86-1086, depsidomycin,kanglemycin-C, spergualin, prodigiosin25-c, cammunomicin, demethomycin,tetranactin, tranilast, stevastelins, myriocin, gliooxin, FR 651814,SDZ214-104, bredinin, WS9482, mycophenolic acid, mimoribine,misoprostol, OKT3, anti-IL-2 receptor antibodies, azasporine,leflunomide, mizoribine, azaspirane (SKF 105685), paclitaxel,altretamine, busulfan, chlorambucil, ifosfamide, mechlorethamine,melphalan, thiotepa, cladribine, fluorouracil, floxuridine, gemcitabine,thioguanine, pentostatin, methotrexate, 6-mercaptopurine, cytarabine,carmustine, lomustine, streptozotocin, carboplatin, cisplatin,oxaliplatin, iproplatin, tetraplatin, lobaplatin, JM216, JM335,fludarabine, aminoglutethimide, flutamide, goserelin, leuprolide,megestrol acetate, cyproterone acetate, tamoxifen, anastrozole,bicalutamide, dexamethasone, diethylstilbestrol, bleomycin,dactinomycin, daunorubicin, doxirubicin, idarubicin, mitoxantrone,losoxantrone, mitomycin-c, plicamycin, paclitaxel, docetaxel, topotecan,irinotecan, 9-amino camptothecan, 9-nitro camptothecan, GS-211,etoposide, teniposide, vinblastine, vincristine, vinorelbine,procarbazine, asparaginase, pegaspargase, octreotide, estramustine, andhydroxyurea, and combinations thereof. In one more particular aspect,the immunosuppressant is cyclosporin A.

Furthermore, the additional therapeutic agent can be selected from thegroup consisting of a chemotherapeutic, a gene therapy vector, a growthfactor, a contrast agent, an angiogenesis factor, a radionuclide, ananti-infection agent, an anti-tumor compound, a receptor-bound agent, ahormone, a steroid, a protein, a complexing agent, a polymer, a thrombininhibitor, an antithrombogenic agent, a tissue plasminogen activator, athrombolytic agent, a fibrinolytic agent, a vasospasm inhibitor, acalcium channel blocker, a nitrate, a nitric oxide promoter, avasodilator, an antihypertensive agent, an antimicrobial agent, anantibiotic, a glycoprotein IIb/IIIa inhibitor, an inhibitor of surfaceglycoprotein receptors, an antiplatelet agent, an antimitotic, amicrotubule inhibitor, a retinoid, an antisecretory agent, an actininhibitor, a remodeling inhibitor, an antisense nucleotide, an agent formolecular genetic intervention, an antimetabolite, an antiproliferativeagent, an anti-cancer agent, a dexamethasone derivative, ananti-inflammatory steroid, a non-steroidal anti-inflammatory agent, animmunosuppressive agent, a PDGF antagonist, a growth hormone antagonist,a growth factor antibody, an anti-growth factor antibody, a growthfactor antagonist, a dopamine agonist, a radiotherapeutic agent, aniodine-containing compound, a barium-containing compound, a heavy metalfunctioning as a radiopaque agent, a peptide, a protein, an enzyme, anextracellular matrix component, a cellular component, an angiotensinconverting enzyme inhibitor, a 21-aminosteroid, a free radicalscavenger, an iron chelator, an antioxidant, a sex hormone, anantipolymerase, an antiviral agent, an IgG2 Kappa antibody againstPseudomonas aeruginosa exotoxin A and reactive with A431 epidermoidcarcinoma cells, monoclonal antibody against the noradrenergic enzymedopamine beta-hydroxylase conjugated to saporin or other antibodytargeted therapy agents, gene therapy agents, a prodrug, a photodynamictherapy agent, and an agent for treating benign prostatic hyperplasia(BHP), a ¹⁴C-, ³H-, ¹³¹I-, ³²P- or ³⁶S-radiolabelled form or otherradiolabelled form of any of the foregoing, and combinations thereof.

More particularly, the additional therapeutic agent can be selected fromthe group consisting of parathyroid hormone, heparin, human growthhormone, covalent heparin, hirudin, hirulog, argatroban,D-phenylalanyl-L-poly-L-arginyl chloromethyl ketone, urokinase,streptokinase, nitric oxide, triclopidine, aspirin, colchicine, dimethylsulfoxide, cytochalasin, deoxyribonucleic acid, methotrexate, tamoxifencitrate, dexamethasone, dexamethasone sodium phosphate, dexamethasone,acetate, cyclosporin, trapidal, angiopeptin, angiogenin, dopamine, ⁶⁰Co,¹⁹²Ir, ³²P, ¹¹¹In, ⁹⁰Y, ^(99m)Tc, pergolide mesylate, bromocriptinemesylate, gold, tantalum, platinum, tungsten, captopril, enalapril,ascorbic acid, α-tocopherol, superoxide dismutase, deferoxamine,estrogen, azidothymidine (AZT), acyclovir, famciclovir, rimantadinehydrochloride, ganciclovir sodium, 5-aminolevulinic acid,meta-tetrahydroxyphenylchlorin, hexadecafluoro zinc phthalocyanine,tetramethyl hematoporphyrin, and rhodamine 123, and combinationsthereof.

Compositions of the invention may comprise one or more immunogenicagents, for example, antigens. Examples of antigens that can be used inthe compositions of the invention (e.g., immunogenic and/or vaccinecompositions) include peptides, proteins, microorganisms (e.g.,attenuated and/or recombinant microorganisms), cells (e.g., cancer cellsand/or recombinant cells) and viruses (e.g., attenuated and/orrecombinant viruses). Examples of peptide antigens include the B subunitof the heat-labile enterotoxin of enterotoxigenic E. coli, the B subunitof cholera toxin, capsular antigens of enteric pathogens, fimbriae orpili of enteric pathogens, HIV surface antigens, cancer antigens (e.g.,cancer cells comprising antigens, isolated antigens, etc.), dustallergens, and acari allergens. Other immunogenic compounds as are knownin the art can also be used.

Examples of attenuated microorganisms and viruses that can be used inthe compositions of the invention (e.g., vaccine compositions) includethose of enterotoxigenic Escherichia coli, enteropathogenic Escherichiacoli, Vibrio cholerae, Shigella flexneri, Salmonella typhi and rotavirus(Fasano et al, In: Le Vaccinazioni in Pediatria, Eds. Vierucci et al,CSH, Milan, pages 109-121 (1991); Guandalini et al, In: Management ofDigestive and Liver Disorders in Infants and Children, Elsevior, Eds.Butz et al, Amsterdam, Chapter 25 (1993); Levine et al, Sem. Ped.Infect. Dis., 5.243-250 (1994); and Kaper et al, Clin. Micrbiol. Rev.,8:48-86 (1995), each of which is incorporated by reference herein in itsentirety).

Any antigen capable of inducing a protective immune response may be usedin the vaccine compositions of the invention. Examples of suitableantigens include, but are not limited to, measles virus antigens, mumpsvirus antigens, rubella virus antigens, Corynebacterium diphtheriaeantigens, Bordetella pertussis antigens, Clostridium tetani antigens,Bacillus anthracis antigens, Haemophilus influenzae antigens, smallpoxvirus antigens, and influenza virus antigens.

Compositions of the invention may further comprise one or more proteaseinhibitors. Any protease inhibitor can be used, including, but notlimited to, a proteinase, peptidase, endopeptidase, or exopeptidaseinhibitor. A cocktail of inhibitors can also be used. Alternatively, theprotease inhibitors can be selected from the group consisting ofbestatin, L-trans-3-carboxyoxiran-2-carbonyl-L-leucylagmatine,ethylenediaminetetra-acetic acid (EDTA), phenylmethylsulfonylfluoride(PMSF), aprotinin, amyloid protein precursor (APP), amyloid betaprecursor protein, α1-proteinase inhibitor, collagen VI, bovinepancreatic trypsin inhibitor (BPTI), 4-(2-aminoethyl)-benzenesulfonylfluoride (AEBSF), antipain, benzamidine, chymostatin, ε-aminocaproate,N-ethylmaleimide, leupeptin, pepstatin A, phosphoramidon, andcombinations thereof. Novel protease inhibitors can also be used.Indeed, protease inhibitors can be specifically designed or selected todecrease the proteolysis of the tight junction agonist and/or thetherapeutic agent.

Compositions of the invention may also comprise one or morepharmaceutically acceptable excipients. Suitable excipients include, butare not limited to, buffers, buffer salts, bulking agents, salts,surface active agents, acids, bases, sugars, binders, and the like.

Methods of Treatment

Compounds and pharmaceutical compositions of the invention can be usedfor treating, ameliorating, and/or preventing a disease. Any disease maybe treated using the compositions of the invention by selection of anappropriate active agent, e.g., therapeutic and/or immunogenic agent. Inone embodiment, the present invention provides a method of treatingdiabetes response in a subject (e.g., a mammal such as a human) byadministering a composition comprising one or more compounds of theinvention together with one or more insulins and/or derivatives thereof.In another embodiment, the invention provides a method of suppressing anexcessive or undesirable immune response in a subject (e.g., a mammalsuch as a human) by administering a composition comprising one or morecompounds of the invention together with one or more immune-suppressivedrugs that may include, for example, cyclosporin A.

Examples of diseases that can be treated using the compositions of theinvention include, but are not limited to, cancer, autoimmune diseases,vascular disease, bacterial infections, gastritis, gastric cancer,collagenous colitis, inflammatory bowel disease, necrotizingenterocolitis, osteoporosis, systemic lupus erythematosus, food allergy,asthma, celiac disease and irritable bowel syndrome. For example, totreat inflammatory bowel disease, a composition comprising one or morecompounds of the invention may be administered to the subject (e.g., amammal such as a human) in need thereof.

In another example, to treat cancer of the colon or rectal area, acomposition comprising a therapeutically effective amount of Erbitux®(Cetuximab) together with a GM-CSF and/or IL-16 inhibiting amount of oneor more compounds of the invention may be administered to the subject(e.g., a mammal such as a human) in need thereof. In another example, totreat breast cancer, a composition comprising a therapeuticallyeffective amount of Herceptin® (Trastuzumab) together with a GM-CSFand/or IL-16 inhibiting amount of one or more compounds of the inventionmay be administered to the subject (e.g., a mammal such as a human) inneed thereof. In another example, to treat various types of cancer, acomposition comprising a therapeutically effective amount of Avastin®(Bevacizumab) together with a GM-CSF and/or IL-16 inhibiting amount ofone or more compounds of the invention may be administered to thesubject (e.g., a mammal such as a human) in need thereof. Anotherexample involves treatment of osteoporosis by administration of acomposition comprising one or more compounds of the invention togetherwith a therapeutically effective amount of Fosamax® (Alendronate) to thesubject in need thereof. Another example involves treatment oftransplant rejection by administration of a composition comprising oneor compounds of the invention together with a therapeutically effectiveamount of Cyclosporin A to the subject in need thereof. Another exampleinvolves treatment of anemia by administration of a compositioncomprising one or more compounds of the invention together with atherapeutically effective amount of erythropoietin to the subject inneed thereof. Another example involves treatment of hemophilia byadministration of a composition comprising one or more compounds of theinvention together with a therapeutically effective amount of FactorVIII to the subject in need thereof.

In some embodiments, compositions of the invention (e.g., pharmaceuticalcompositions) may be given repeatedly over a protracted period, i.e.,may be chronically administered. Typically, compositions may beadministered one or more times each day in an amount suitable toprevent, reduce the likelihood of an attack of, or reduce the severityof an attack of the underlying disease condition (e.g., diabetes,cancer, transplant rejection, etc). Such compositions may beadministered chronically, for example, one or more times daily over aplurality of days.

In some embodiments, compositions of the invention (e.g., pharmaceuticalcompositions) may be used to treat acute attacks of the underlyingdisease (e.g., diabetes, cancer, transplant rejection, etc). Typically,embodiments of this type will require administration of the compositionsof the invention to a subject undergoing an attack in an amount suitableto reduce the severity of the attack. One or more administrations may beused.

In some embodiments, compounds of the invention may be used in themanufacture of compositions and pharmaceutical compositions for use inthe methods described above.

While the invention has been described with reference to certainparticular embodiments thereof, those skilled in the art will appreciatethat various modifications may be made without departing from the spiritand scope of the invention. The scope of the appended claims is not tobe limited to the specific embodiments described.

Methods of Screening

Screening for inhibitors of gliadin-derived peptide translocation acrossbiological barriers can be accomplished by a variety of techniques.Likewise, screening for inhibitors of PTG-induced factors that increasebiological barrier permeability can be accomplished by a variety oftechniques. Gliadin-derived peptide binding to test compounds (inhibitorcandidates) can be directly measured, or inhibition of binding ofgliadin-derived peptides to a cell preparation can be measured.Gliadin-derived peptides can be labeled to facilitate measurement ofbinding. Assays may be in cell-free systems or in cell-based systems.Any binding assay format can be used, including formats where thereceptor is attached to a solid support, either directly or indirectly.

Test compounds which can be tested are any compounds. The compounds maybe tested as single compounds or in combinations of compounds. Thecompounds may be structurally identified or of unknown structure. Thecompounds may be novel or previously known. The compounds may be naturalproducts or synthetic.

According to one embodiment of the invention the test compounds arefragments of gliadin. Gliadin is a family of proteins which are producedby wheat and other grains. Examples of gliadins are gliadin alpha,gamma, and omega. Gliadins are the aqueous alcohol-soluble storageproteins in the seed. There is great heterogeneity even within a singleclass of gliadins. At least six, seven, eight, nine, ten, eleven,fifteen, twenty, thirty, thirty-five, fifty, or seventy-five amino acidresidues may be used in fragments of gliadin as test compounds.Fragments include any molecule which is less than full length. Fragmentsmay be, e.g., synthesized or the result of proteolytic degradation. Thefollowing tables provide the sequences of a representative number ofgliadins.

TABLE 1 Amino acid sequence of alpha-gliadin from Triticum aestivum(NCBI accession no. CAB76964, (SEQ ID NO: 165)) 1 mvrvpvpqlq pqnpsqqqpqeqvplvqqqq fpgqqqpfpp qqpypqpqpf 51 psqqpylqlq pfpqpqlpyp qpqlpypqpqlpypqpqpfr pqqpypqsqp 101 qysqpqqpis qqqqqqqqqq qqkqqqqqqq qilqqilqqqlipcrdvvlq 151 qhsiaygssq vlqqstyqlv qqlccqqlwq ipeqsrcqai hnvvhaiilh201 qqqqqqqqqq qqplsqvsfq qpqqqypsgq gsfqpsqqnp qaqgsvqpqq 251lpqfeeirnl aletlpamcn vyippyctia pvgifgtnyr

TABLE 2 Amino acid sequence of alpha-gliadin precursor from Triticumturgidum subsp. durum (NCBI accession no. CA135909, (SEQ ID NO: 166)) 1mktflilall aivattatta vrvpvpqlqr qnpsqqqpqe qvplvqqqqf 51 lgqqqpfppqqpypqpqpfp sqqpylqlqp fpqpqlpysq pqpfrpqqpy 101 pqpqprysqp qqpisqqqqqqhqqhqqhhq eqqilqqilq qqlipcmdvv 151 lqqhniahrr sqvlqqstyq llqelccqhlwqipeqsqcq aihnvvhaii 201 phqqqkqqqq pssqfsfqqp lqqyplgqgs frpsqqnpqaqgsvqpqqlp 251 qfeeirnlal qtlpamcnvy ippyctiapf gifgtn

TABLE 3 Amino acid sequence of alpha/beta-gliadin precursor fromTriticum aestivum (NCBI accession no. AAA34280, (SEQ ID NO: 167)) 1mktflilvll aivattatta vrfpvpqlqp qnpsqqqpqe qvplvqqqqf 51 lgqqqpfppqqpypqpqpfp sqlpylqlqp fpqpqlpysq pqpfrpqqpy 101 pqpqpqysqp qqpisqqqqqqqqqqqqqqq qqqilqqilq qqlipcmdvv 151 lqqhniahgr sqvlqqstyq llqelccqhlwqipeqsqcq aihnvvhaii 201 lhqqqkqqqq pssqvsfqqp lqqyplgqgs frpsqqnpqaqgsvqpqqlp 251 qfeeirnlal qtlpamcnvy ippyctiapf gifgtn

TABLE 4 Amino acid sequence of Gamma-gliadin precursor from Triticumaestivum (NCBI accession no. P21292, (SEQ ID NO: 168)) 1 mktlliltilamattiatan mqvdpsgqvq wpqqqpfpqp qqpfcqqpqr 51 tipqphqtfh hqpqqtfpqpqqtyphqpqq qfpqtqqpqq pfpqpqqtfp 101 qqpqlpfpqq pqqpfpqpqq pqqpfpqsqqpqqpfpqpqq qfpqpqqpqq 151 sfpqqqqpai qsflqqqmnp cknfllqqcn hvslvsslvsiilprsdcqv 201 mqqqccqqla qipqqlqcaa ihsvahsiim qqeqqqgvpi lrplfqlaqg251 lgiiqpqqpa qlegirslvl ktlptmcnvy vppdcstinv pyanidagig 301 gq

TABLE 5 Amino acid sequence of Gamma-gliadin B precursor from Triticumaestivum (NCBI accession no. P06659, (SEQ ID NO: 169)) 1 mktlliltilamaitiatan mqadpsgqvq wpqqqpflqp hqpfsqqpqq 51 ifpqpqqtfp hqpqqqfpqpqqpqqqflqp rqpfpqqpqq pypqqpqqpf 101 pqtqqpqqpf pqskqpqqpf pqpqqpqqsfpqqqpsliqq slqqqlnpck 151 nfllqqckpv slvsslwsii lppsdcqvmr qqccqqlaqipqqlqcaaih 201 svvhsiimqq eqqeqlqgvq ilvplsqqqq vgqgilvqgq giiqpqqpaq251 levirslvlq tlptmcnvyv ppycstirap fasivasigg q

TABLE 6 Amino acid sequence of Gamma-gliadin (Gliadin B-III) fromTriticum aestivum (NCBI accession no. P04730, (SEQ ID NO: 170)) 1pqqpfplqpq qsflwqsqqp flqqpqqpsp qpqqvvqiis patpttipsa 51 gkptsapfpqqqqqhqqlaq qqipvvqpsi lqqlnpckvf lqqqcspvam 101 pqrlarsqml qqsschvmqqqccqqlpqip qqsryqaira iiysiilqeq 151 qqvqgsiqsq qqqpqqlgqc vsqpqqqsqqqlgqqpqqqq laqgtflqph 201 qiaqlevmts ialrilptmc svnvplyrtt tsvpfgvgtgvgay

TABLE 7 Amino acid sequence of Gamma-gliadin precursor from Triticumaestivum (NCBI accession no. P08453, (SEQ ID NO: 171)) 1 mktlliltilamaitigtan iqvdpsgqvq wlqqqlvpql qqplsqqpqq 51 tfpqpqqtfp hqpqqqvpqpqqpqqpflqp qqpfpqqpqq pfpqtqqpqq 101 pfpqqpqqpf pqtqqpqqpf pqqpqqpfpqtqqpqqpfpq lqqpqqpfpq 151 pqqqlpqpqq pqqsfpqqqr pfiqpslqqq lnpcknillqqskpaslvss 201 lwsiiwpqsd cqvmrqqccq qlaqipqqlq caaihsvvhs iimqqqqqqq251 qqqgidiflp lsqheqvgqg slvqgqgiiq pqqpaqleai rslvlqtlps 301mcnvyvppec simrapfasi vagiggq

TABLE 8 Amino acid sequence of Gamma-gliadin B-I precursor from Triticumaestivum (NCBI accession no. P04729, (SEQ ID NO: 172)) 1 mktflvfaliavvatsaiaq metscisgle rpwqqqplpp qqsfsqqppf 51 sqqqqqplpq qpsfsqqqppfsqqqpilsq qppfsqqqqp vlpqqspfsq 101 qqqlvlppqq qqqqlvqqqi pivqpsvlqqlnpckvflqq qcspvampqr 151 larsqmwqqs schvmqqqcc qqlqqipeqs ryeairaiiysiilqeqqqg 201 fvqpqqqqpq qsgqgvsqsq qqsqqqlgqc sfqqpqqqlg qqpqqqqqqq251 vlqgtflqph qiahleavts ialrtlptmc svnvplysat tsvpfgvgtg 301 vgay

TABLE 9 Amino acid sequence of Gamma-gliadin precursor from Triticumaestivum (NCBI accession no. P08079, (SEQ ID NO: 173)) 1 mktlliltilamaitigtan mqvdpssqvq wpqqqpvpqp hqpfsqqpqq 51 tfpqpqqtfp hqpqqqfpqpqqpqqqflqp qqpfpqqpqq pypqqpqqpf 101 pqtqqpqqlf pqsqqpqqqf sqpqqqfpqpqqpqqsfpqq qppfiqpslq 151 qqvnpcknfl lqqckpvslv sslwsmiwpq sdcqvmrqqccqqlaqipqq 201 lqcaaihtii hsiimqqeqq eqqqgmhill plyqqqqvgq gtlvqgqgii251 q

TABLE 10 Amino acid sequence of Alpha/beta-gliadin MM1 precursor(Prolamin) from Triticum aestivum (NCBI accession no. P18573, (SEQ IDNO: 174)) 1 mktflilall aivattaria vrvpvpqlqp qnpsqqqpqe qvplvqqqqf 51pgqqqpfppq qpypqpqpfp sqqpylqlqp fpqpqlpypq pqlpypqpql 101 pypqpqpfrpqqpypqsqpq ysqpqqpisq qqqqqqqqqq qkqqqqqqqq 151 ilqqilqqql ipcrdvvlqqhsiaygssqv lqqstyqlvq qlccqqlwqi 201 peqsrcqaih nvvhaiilhq qqqqqqqqqqqplsqvsfqq pqqqypsgqg 251 sfqpsqqnpq aqgsvqpqql pqfeeirnla letlpamcnvyippyctiap 301 vgifgtn

TABLE 11 Amino acid sequence of Alpha/beta-gliadin clone PTO-A10(Prolamin) from Triticum aestivum (NCBI accession no. P04728, (SEQ IDNO: 175)) 1 pqpqpqysqp qqpisqqqqq qqqqqqqqqq eqqilqqilq qqlipcmdvv 51lqqhniahgr sqvlqqstyq llqelccqhl wqipeqsqcq aihnvvhaii 101 lhqqqqkqqqqpssqfsfqq plqqyplgqg sfrpsqqnpq aqgsvqpqql 151 pqfeirnlal qtlpamcnvyippyctiapf gifgtn

TABLE 12 Amino acid sequence of Alpha/beta-gliadin clone PW8142precursor (Prolamin) from Triticum aestivum (NCBI accession no. P04727,(SEQ ID NO: 176)) 1 mktflilalv attattavrv pvpqlqpknp sqqqpqeqvplvqqqqfpgq 51 qqqfppqqpy pqpqpfpsqq pylqlqpfpq pqpflpqlpy pqpqsfppqq 101pypqqrpkyl qpqqpisqqq aqqqqqqqqq qqqqqqqqil qqilqqqlip 151 crdvvlqqhniahassqvlq qstyqllqql ccqqllqipe qsrcqaihnv 201 vhaiimhqqe qqqqlqqqqqqqlqqqqqqq qqqqqpssqv sfqqpqqqyp 251 ssqgsfqpsq qnpqaqgsvq pqqlpqfaeirnlalqtlpa mcnvyipphc 301 sttiapfgif gtn

TABLE 13 Amino acid sequence of Alpha/beta-gliadin clone PW1215precursor (Prolamin) from Triticum aestivum (NCBI accession no. P04726,(SEQ ID NO: 177)) 1 mktflilall aivattatta vrvpvpqpqp qnpsqpqpqgqvplvqqqqf 51 pgqqqqfppq qpypqpqpfp sqqpylqlqp fpqpqpfppq lpypqpppfs 101pqqpypqpqp qypqpqqpis qqqaqqqqqq qqqqqqqqqq qqilqqilqq 151 qlipcrdvvlqqhniahars qvlqqstyqp lqqlccqqlw qipeqsrcqa 201 ihnvvhaiil hqqqrqqqpssqvslqqpqq qypsgqgffq psqqnpqaqg 251 svqpqqlpqf eeirnlalqt lprmcnvyippycsttiapf gifgtn

TABLE 14 Amino acid sequence of Alpha/beta-gliadin A-IV precursor(Prolamin) from Triticum aestivum (NCBI accession no. P04724, (SEQ IDNO: 178)) 1 mktflilalr aivattatia vrvpvpqlqp qnpsqqqpqk qvplvqqqqf 51pgqqqpfppq qpypqqqpfp sqqpymqlqp fpqpqlpypq pqlpypqpqp 101 frpqqsypqpqpqysqpqqp isqqqqqqqq qqqqqqqilq qilqqqlipc 151 rdvvlqqhsi ahgssqvlqqstyqlvqqfc cqqlwqipeq srcqaihnvv 201 haiilhqqqq qqqqqqqqqq qplsqvcfqqsqqqypsgqg sfqpsqqnpq 251 aqgsvqpqql pqfeeirnla letlpamcnv yippyctiapvgifgtn

TABLE 15 Amino acid sequence of Alpha/beta-gliadin A-III precursor(Prolamin) from Triticum aestivum (NCBI accession no. P04723, (SEQ IDNO: 179)) 1 mktflilall aivattatsa vrvpvpqlqp qnpsqqqpqe qvplmqqqqq 51fpgqqeqfpp qqpyphqqpf psqqpypqpq pfppqlpypq tqpfppqqpy 101 pqpqpqypqpqqpisqqqaq qqqqqqqtlq qilqqqlipc rdvvlqqhni 151 ahassqvlqq ssyqqlqqlccqqlfqipeq srcqaihnvv haiilhhhqq 201 qqqqpssqvs yqqpqeqyps gqvsfqssqqnpqaqgsvqp qqlpqfqeir 251 nlalqtlpam cnvyippycs ttiapfgifg tn

TABLE 16 Amino acid sequence of Alpha/beta-gliadin A-II precursor(Prolamin) from Triticum aestivum (NCBI accession no. P04722, (SEQ IDNO: 180)) 1 mktfpilall aivattatta vrvpvpqlql qnpsqqqpqe qvplvqeqqf 51qgqqqpfppq qpypqpqpfp sqqpylqlqp fpqpqlpypq pqpfrpqqpy 101 pqpqpqysqpqqpisqqqqq qqqqqqqqqq ilqqilqqql ipcrdvvlqq 151 hniahgssqv lqestyqlvqqlccqqlwqi peqsrcqaih nvvhaiilhq 201 qhhhhqqqqq qqqqqplsqv sfqqpqqqypsgqgffqpsq qnpqaqgsfq 251 pqqlpqfeei rnlalqtlpa mcnvyippyc tiapfgifgt n

TABLE 17 Amino acid sequence of Alpha/beta-gliadin A-I precursor(Prolamin) from Triticum aestivum (NCBI accession no. P04721, (SEQ IDNO: 181)) 1 mktflilall aivattatta vrvpvpqlqp qnpsqqqpqe qvplvqqqqf 51lgqqqpfppq qpypqpqpfp sqqpylqlqp flqpqlpysq pqpfrpqqpy 101 pqpqpqysqpqqpisqqqqq qqqqqqqqqq qqqqiiqqil qqqlipcmdv 151 vlqqhnivhg ksqvlqqstyqllqelccqh lwqipeqsqc qaihnvvhai 201 ilhqqqkqqq qpssqvsfqq plqqyplgqgsfrpsqqnpq aqgsvqpqql 251 pqfeeirnla rk

TABLE 18 Amino acid sequence of gamma gliadin from Triticum aestivum(NCBI accession no. AAQ63860, (SEQ ID NO: 182)) 1 mniqvdpssq vpwpqqqpfpqphqpfsqqp qqtfpqpqqt fphqpqqqfs 51 qpqqpqqqfi qpqqpfpqqp qqtypqrpqqpfpqtqqpqq pfpqsqqpqq 101 pfpqpqqqfp qpqqpqqsfp qqqpsliqqs lqqqlnpcknfllqqckpvs 151 lvsslwsmil prsdcqvmrq qccqqlaqip qqlqcaaihs ivhsiimqqe201 qqeqrqgvqi lvplsqqqqv gqgtlvqgqg iiqpqqpaql evirslvlqt 251latmcnvyvp pycstirapf asivagiggq yr

TABLE 19 Amino acid sequence of Omega-gliadin from Triticum monococcum(NCBI accession no. P02865, (SEQ ID NO: 183)) 1 arqlnpsdqe lqspqqlypqqpypqqpy

Inhibitors of gliadin-derived peptide translocation across biologicalbarriers are useful for treating diseases characterized by inflammation,including autoimmune diseases and particularly including celiac disease.Inhibitors of PTG-induced factors that increase biological barrierpermeability are useful for treating diseases characterized byinflammation, including autoimmune diseases and particularly includingceliac disease.

Activity of inhibitors of gliadin-derived peptide translocation and/orinhibitors of PTG-induced permeability can be measured by any meansknown in the art. Signaling events which can be determined includedecrease in TEER, increase in LY permeability, increase in cytokinerelease, microglial recruitment, tyrosine kinase phosphorylation andchemotaxis, and increase in MMP-2 and MMP-9 gelatinolytic activity incell-conditioned media.

The invention provides methods of identifying agents, compounds or leadcompounds for agents active in inhibiting PTG-induced alterations inbiological barrier permeability and/or peptide translocation. Generally,screening methods of the invention involve assaying for compounds whichmodulate the interaction of one or more gliadin fragments with one ormore cells (e.g., epithelial cells, immune cells). A wide variety ofassays for binding agents is provided including labeled in vitroprotein-ligand binding assays, cell based assays, immunoassays, etc. Awide variety of formats may be used, including co-immunoprecipitation,2-hybrid transactivation, fluorescent polarization, NMR, fluorescentresonance energy transfer (FRET), transcriptional activation, etc. Forexample, a wide variety of NMR-based methods are available to rapidlyscreen libraries of small compounds for binding to protein targets(Hajduk, P. J., et al. Quarterly Reviews of Biophysics, 1999. 32 (3):211-40). In some embodiments, methods of the invention may be automated(e.g., high throughput screening) and may be used to screen chemicallibraries for lead compounds. Identified compounds may be used to treatdiseases involving increased biological barrier permeability including,for example, celiac disease, inflammatory bowel diseases and autoimmunediseases. Compounds identified by the methods of the invention may befurther optimized to modulate biological barrier modulation, forexample, may be derivatized. Multiple iterations of screening andderivatization may be employed to optimize the modulation of biologicalbarrier permeability.

In vitro ligand binding assays employ a mixture of components includingone or more gliadin-derived peptides or fragments and one or moregliadin binding components. Gliadin-derived peptides or fragments may beprovided as fusion proteins (e.g., with purification tags such as6-His). Assay mixtures typically further comprise a compound to betested for inhibitory activity. Compounds to be tested may be of anykind known to those skilled in the art, for example, may be organiccompounds, peptides, proteins, nucleic acids, lipids, carbohydrates andmixtures thereof. A variety of other reagents may also be included inthe mixture including, but not limited to, salts, buffers, neutralproteins, e.g. albumin, detergents, protease inhibitors, nucleaseinhibitors, antimicrobial agents, etc.

In general, assay mixtures may be incubated under conditions in which,but for the presence of the compound to be tested, gliadin-derivedpeptides or fragments specifically bind the gliadin binding componentswith a reference binding affinity. The mixture components can be addedin any order that provides for the requisite bindings and incubationsmay be performed at any temperature which facilitates optimal binding.Incubation periods are likewise selected for optimal binding. In someembodiments, incubation periods may be minimized to facilitate rapid,high-throughput screening.

After incubation, the effect of the compound to be tested on the gliadinbinding may be detected by any convenient way. For example, thegliadin-derived peptide or fragment or the gliadin binding component maybe immobilized, and the other labeled; then in a solid-phase format, anyof a variety of methods may be used to detect the label depending on thenature of the label and other assay components, e.g. through optical orelectron density, radiative emissions, nonradiative energy transfers,etc. or indirectly detected with antibody conjugates, etc.

A difference in the binding affinity of the gliadin-derived peptide orfragment and the gliadin binding component in the absence of thecompound to be tested as compared with the binding affinity in thepresence of the compound to be tested indicates that the compoundmodulates the binding of the gliadin-derived peptide or fragment and thegliadin binding component. A difference, as used herein, isstatistically significant and preferably represents at least a 50%, 60%,70%, 80%, or 90% difference.

The above disclosure generally describes the present invention. Allreferences disclosed herein are expressly incorporated by reference. Amore complete understanding can be obtained by reference to thefollowing specific examples which are provided herein for purposes ofillustration only, and are not intended to limit the scope of theinvention.

Example 1 Measurement of Trans Epithelial Electric Resistance (TEER) andEpithelial Flux of a Fluorescent Marker Lucifer Yellow

CaCo2 cells form monolayers that exhibit tight junctions betweenadjacent cells. Agonists of tight junctions can be identified by theirability to enhance the flux of compounds (e.g. ions, Lucifer Yellow)through a cell monolayer that comprises tight junctions; or by theirability to reduce TEER across a cell monolayer that comprises tightjunctions. Treatment of CaCo2 monolayers with peptide tight junctionagonist compounds leads to enhancement of Lucifer Yellow permeabilitythrough CaCo2 monolayers compared to vehicle alone. Treatment of CaCo2monolayers with peptide tight junction agonist compounds leads to adecrease in TEER across CaCo2 monolayers compared to vehicle alone.

Tight junction agonists and agonists of the C1orf43 and CCDC78 proteinscan be identified using the following method, and this method may beeasily modified to identify antagonists and inhibitors of the C1orf43and CCDC78 proteins:

Determination of TEER and Lucifer Yellow Flux

Prepare Modified Hank's Balanced Salt Solution (MHBSS) by obtaining 1 Lbottle of HBSS removing 10 ml of HBSS and replacing it with 10 ml HEPESbuffer pH 7.0. Adjust pH to 7.4±0.1 using concentrated NaOH (10N).

Remove CaCo-2 cells from incubator, grown on 12-well, 3.0 μM,polycarbonate Transwell® filters (Corning) and record passage#, datecells seeded and age in days.

Aspirate cell culture medium from both the apical (ΔP) and basolateral(BL) compartments, replacing with 0.5 ml and 1.5 ml of MHBSS,respectively. Incubate cells at 37° C. for 30 minutes.

Using the MilliCell®-ERS instrument (Millipore), measure and record thetransepithelial electrical resistance (TEER) across each filter andrecord.

Aspirate solution from the apical compartment of each filter (n=3 percondition) and replace with 0.5 ml of control and test solutionscontaining Lucifer Yellow and test compound if appropriate.

Place all plates into incubator set at 37° C. (±0.2), 50 RPM (±5) for atotal of 180 minutes.

At t=30, 60, 120 and 180 minutes, measure and record the transepithelialelectrical resistance (TEER) across each filter using the MilliCell-ERSinstrument.

At t=60, 120 and 180 minutes remove 100 μl from each basolateralcompartment and place it in a 96-well plate for Lucifer Yellow analysis,replace with 100 μl of MHBSS.

Make a Lucifer Yellow standard curve with the following dilutions (7500μM, 3750 μM, 750 μM, 375 μM, 75 μM, 37.5 μM, 7.5 μM, 3.75 μM, 0.75 μM)and pipette 100 μL of each into a 96-well plate except for the firstthree standards mentioned above which require a 1:10 dilutions prior totransferring to the 96-well plate.

Harvest the remaining start solutions and what is left in each apicalcompartment into 1.5 ml vials. Freeze at −20° C. for future analysis.

Analyze each 96-well plate in a Tecan Spectra Fluor Plus using Magellanat 485 and 535 nm.

Materials:

Cells: CaCo-2 cells passage 40-60 grown on Transwell® plates for 21-28days

Culture Medium: DMEM supplemented with 10% fetal bovine serum, 1% NEAA,1% Penn/Strep

Buffers: Hank's Balanced Salt Solution (HBSS) without calcium andmagnesium

Flasks: 100×20 mm Tissue culture dish Falcon.

Plates: 12 well polycarbonate Transwell® filters; 0.3 uM pore size

Example 2 Identification of Cytokines Upregulated on Treatment of THP-1Cells by PT-Gliadin (PTG)

The monocytic cell line THP-1 was used to characterize the profile ofcytokines whose expression was upregulated on exposure to proteasetreated gliadin (PTG). THP-1 cells were diluted to 5×10⁵ cells/ml inRPMI medium supplemented with 10% heat inactivated fetal bovine serum.

5×10⁵ (1 ml) cells were plated in each well of a 12 well plate, andcells were incubated at 37° C. overnight. Test compounds (PTG 1 mg/ml;LPS 1 μg/ml) were added to the cultures, and incubation was continued afurther 18 hours at 37° C.

Culture supernatants were harvested, and cytokines/chemokines weremeasured in each sample using a nitrocellulose membrane based proteomicprofiler assay (R&D Systems). Assays were performed in triplicate. Thecytokines screened in this assay included C5a, CD40 ligand, G-CSF,GM-CSF, GRO-α/CXCL1, I-309/CCL1, ICAM-1, IFNγ, IL-1α, IL-1β, IL-1ra,IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-16, IL-17,IL-17E, IL-23, IL-27, IL-32α, IP-10/CXCL10, 1-TAC/CXCL11, MCP-1/CCL2,MIF, MIP-1α/CCL3, MIP-1β/CCL3, RANTES/CCL5, SDF-1/CXCL12,Serpin-E1/PAI-1, TNFα, and TREM-1.

After 6 hours of PTG exposure THP-1 cells demonstrated increasedexpression of the cytokines IL-8, MIP-1α, MIP-1β, TNF-α and Gro-α. After24 hours of exposure to PTG increased expression of RANTES and MIF werealso observed.

Example 3 Identification of Cytokines Upregulated on Treatment of PBMCsby PT-Gliadin (PTG)

Peripheral blood mononuclear cells were isolated from donated humanblood samples using methods known in the art, and these PBMCs were usedto characterize the profile of cytokines whose expression wasupregulated on exposure to protease treated gliadin (PTG). PBMCs weresuspended in RPMI medium supplemented with 5% heat inactivated human ABserum, and 2×10⁵ cells were plated in each well of a 96 well plate.Cells were incubated at 37° C. with PTG (1 mg/ml) or LPS (1 μg/ml) inthe presence or absence of test compounds being examined for the abilityto suppress cytokine production. Supernatant samples were harvestedfollowing treatment, and cytokines were assayed by ELISA (R&D Systems).

Expression of IL-6, IL-8, MIP-1α, and Gro-α were induced by treatmentwith LPS and PTG. Expression of these cytokines was not reduced bytreatment with peptide GGVLVQPG (SEQ ID NO:1).

Increased expression of GM-CSF and IL-16 was induced by exposure to LPSand PTG. This increased expression of these cytokines was inhibited bytreatment with peptide GGVLVQPG (SEQ ID NO:1).

Having now fully described the present invention in some detail by wayof illustration and example for purposes of clarity of understanding, itwill be obvious to one of ordinary skill in the art that the same can beperformed by modifying or changing the invention within a wide andequivalent range of conditions, formulations and other parameterswithout affecting the scope of the invention or any specific embodimentthereof, and that such modifications or changes are intended to beencompassed within the scope of the appended claims. All publications,patents and patent applications mentioned in this specification areindicative of the level of skill of those skilled in the art to whichthis invention pertains, and are herein incorporated by reference to thesame extent as if each individual publication, patent or patentapplication was specifically and individually indicated to beincorporated by reference.

TABLE 20 Peptide permeability inhibitors Prevented TEER Reduced LY SEQID NO: Sequence Reduction Permeability 1 Gly-Gly-Val-Leu-Val-Gln-Pro-Gly− + 2 Ala-Gly-Val-Leu-Val-Gln-Pro-Gly − + 3Gly-Ala-Val-Leu-Val-Gln-Pro-Gly − + 4 Gly-Gly-Ala-Leu-Val-Gln-Pro-Gly− + 5 Gly-Gly-Val-Ala-Val-Gln-Pro-Gly − + 6Gly-Gly-Val-Leu-Ala-Gln-Pro-Gly − − 7 Gly-Gly-Val-Leu-Val-Ala-Pro-Gly −− 8 Gly-Gly-Val-Leu-Val-Gln-Ala-Gly − − 9Gly-Gly-Val-Leu-Val-Gln-Pro-Ala − − 10Gly-Asp-Val-Leu-Val-Gln-Pro-Gly + + 11Gly-Glu-Val-Leu-Val-Gln-Pro-Gly + + 12Gly-Gln-Val-Leu-Val-Gln-Pro-Gly + + 13Gly-Phe-Val-Leu-Val-Gln-Pro-Gly + + 14Gly-His-Val-Leu-Val-Gln-Pro-Gly + + 15Gly-Arg-Val-Leu-Val-Gln-Pro-Gly + + 16Gly-Lys-Val-Leu-Val-Gln-Pro-Gly + + 17Gly-Ile-Val-Leu-Val-Gln-Pro-Gly + + 18 Gly-Trp-Val-Leu-Val-Gln-Pro-Gly −− 19 Gly-Pro-Val-Leu-Val-Gln-Pro-Gly + + 20Gly-Val-Val-Leu-Val-Gln-Pro-Gly + + 21Gly-Leu-Val-Leu-Val-Gln-Pro-Gly + + 22Gly-Asn-Val-Leu-Val-Gln-Pro-Gly + + 23Gly-Thr-Val-Leu-Val-Gln-Pro-Gly + + 24 Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly −− 25 Gly-Gly-Leu-Leu-Val-Gln-Pro-Gly − − 26Gly-Gly-Ile-Leu-Val-Gln-Pro-Gly − − 27Gly-Gly-Phe-Leu-Val-Gln-Pro-Gly + + 28 Gly-Gly-Arg-Leu-Val-Gln-Pro-Gly −− 29 Gly-Gly-Asp-Leu-Val-Gln-Pro-Gly − − 30Gly-Gly-Gln-Leu-Val-Gln-Pro-Gly − − 31 Gly-Gly-His-Leu-Val-Gln-Pro-Gly −− 32 Gly-Gly-Met-Leu-Val-Gln-Pro-Gly + + 33Gly-Gly-Ser-Leu-Val-Gln-Pro-Gly − − 34Gly-Gly-Thr-Leu-Val-Gln-Pro-Gly + + 35 Gly-Gly-Pro-Leu-Val-Gln-Pro-Gly −− 36 Gly-Gly-Val-Gly-Val-Gln-Pro-Gly + + 37Gly-Gly-Val-Val-Val-Gln-Pro-Gly − − 38 Gly-Gly-Val-Ile-Val-Gln-Pro-Gly −− 39 Gly-Gly-Val-Phe-Val-Gln-Pro-Gly − − 40Gly-Gly-Val-Arg-Val-Gln-Pro-Gly − − 41 Gly-Gly-Val-Asp-Val-Gln-Pro-Gly −− 42 Gly-Gly-Val-Gln-Val-Gln-Pro-Gly − − 43Gly-Gly-Val-His-Val-Gln-Pro-Gly − − 44 Gly-Gly-Val-Met-Val-Gln-Pro-Gly −− 45 Gly-Gly-Val-Ser-Val-Gln-Pro-Gly − − 46Gly-Gly-Val-Thr-Val-Gln-Pro-Gly − − 47 Gly-Gly-Val-Pro-Val-Gln-Pro-Gly −− 48 D-Ala-Gly-Val-Leu-Val-Gln-Pro-Gly + + 49Asp-Gly-Val-Leu-Val-Gln-Pro-Gly + + 50 Glu-Gly-Val-Leu-Val-Gln-Pro-Gly −− 51 Gln-Gly-Val-Leu-Val-Gln-Pro-Gly NT NT 52Phe-Gly-Val-Leu-Val-Gln-Pro-Gly NT NT 53 His-Gly-Val-Leu-Val-Gln-Pro-GlyNT NT 54 Arg-Gly-Val-Leu-Val-Gln-Pro-Gly − − 55Lys-Gly-Val-Leu-Val-Gln-Pro-Gly + + 56 Ile-Gly-Val-Leu-Val-Gln-Pro-Gly −− 57 Trp-Gly-Val-Leu-Val-Gln-Pro-Gly − − 58Pro-Gly-Val-Leu-Val-Gln-Pro-Gly + + 59 Val-Gly-Val-Leu-Val-Gln-Pro-Gly −− 60 Leu-Gly-Val-Leu-Val-Gln-Pro-Gly − − 61Thr-Gly-Val-Leu-Val-Gln-Pro-Gly NT NT 62 Asn-Gly-Val-Leu-Val-Gln-Pro-GlyNT NT 63 D-Phe-Gly-Val-Leu-Val-Gln-Pro-Gly − − 64Cha-Gly-Val-Leu-Lav-Gln-Pro-Gly NT NT 65Met(O)2-Gly-Val-Leu-Val-Gln-Pro-Gly NT NT 66 Gly-Val-Leu-Val-Gln-Pro-Gly− − 67 Val-Leu-Val-Gln-Pro-Gly + + 68 Leu-Val-Gln-Pro-Gly + + 69Val-Gln-Pro-Gly + + 70 Gln-Pro-Gly + + 71 Gly-Gly-Val-Leu-Val-Gln-Pro− + 72 Gly-Gly-Val-Leu-Val-Gln + + 73 Gly-Gly-Val-Leu-Val + + 74Gly-Gly-Val-Leu + + 75 Gly-Gly-Val + + 76Gly-Gly-D-Val-Leu-Val-Gln-Pro-Gly + + 77Gly-Gly-Val-D-Leu-Val-Gln-Pro-Gly + + 78Gly-Gly-Val-Leu-D-Val-Gln-Pro-Gly − − 79Gly-Gly-Val-Leu-Val-D-Gln-Pro-Gly + + 80Gly-Gly-Val-Leu-Val-Gln-D-Pro-Gly + + 81Gly-D-Pro-D-Gln-D-Val-D-Leu-D-Val- + + Gly-Gly 82Gly-D-Pro-D-Gln-D-Val-D-Leu-Val-Gly- + + Gly 83Gly-D-Pro-D-Gln-D-Val-Leu-D-Val-Gly- + + Gly 84Gly-D-Pro-D-Gln-Val-D-Leu-D-Val-Gly- + + Gly 85Gly-D-Pro-Gln-D-Val-D-Leu-D-Val-Gly- + + Gly 86Gly-Pro-D-Gln-D-Val-D-Leu-D-Val-Gly- − − Gly 87Gly-Pro-Gln-Val-Leu-Val-Gly-Gly + + 88Gly-D-Pro-Gln-Val-Leu-Val-Gly-Gly + + 89Gly-Pro-D-Gln-Val-Leu-Val-Gly-Gly − − 90Gly-Pro-Gln-D-Val-Leu-Val-Gly-Gly − − 91Gly-Pro-Gln-Val-D-Leu-Val-Gly-Gly + + 92Gly-Pro-Gln-Val-Leu-D-Val-Gly-Gly + + 93Gly-Gly-D-Val-D-Leu-D-Val-D-Gln-D- Pro-Gly 94Gly-Gly-D-Val-D-Leu-D-Val-D-Gln-Pro- + − Gly 95Gly-Gly-D-Val-D-Leu-D-Val-Gln-D-Pro- − − Gly 96Gly-Gly-D-Val-D-Leu-Val-D-Gln-D-Pro- − − Gly 97Gly-Gly-D-Val-Leu-D-Val-D-Gln-D-Pro- − − Gly 98Gly-Gly-Val-D-Leu-D-Val-D-Gln-D-Pro- + + Gly 99Gly-D-Phe-Val-Leu-Val-Gln-Pro-Gly + + 100 Ala-Pro-Gly + + 101Gln-Ala-Gly + + 102 Gln-Pro-Ala + + 103 (d)Gln-Pro-Gly + + 104Gln-(d)Pro-Gly + + 105 (d)Gln-(d)Pro-Gly − − 106 Gly-Pro-Gln + + 107Gly-(d)Pro-Gln − − 108 Gly-Pro-(d)Gln − − 109 Gly-(d)Pro-(d)Gln − − 110Ala-Pro-Gly + + 111 His-Pro-Gly + + 112 Asp-Pro-Gly − − 113Arg-Pro-Gly + + 114 Phe-Pro-Gly + + 115 Gly-Pro-Gly + + 116Glu-Pro-Gly + + 117 Lys-Pro-Gly + + 118 Leu-Pro-Gly + + 119Met-Pro-Gly + + 120 Asn-Pro-Gly + + 121 Ser-Pro-Gly + + 122Tyr-Pro-Gly + + 123 Thr-Pro-Gly − + 124 Ile-Pro-Gly + + 125Trp-Pro-Gly + + 126 Pro-Pro-Gly − − 127 Val-Pro-Gly − + 128Glp-Pro-Gly + + 129 Glp-Val-Gly − − 130 Glp-Gln-Gly − − 131 Glp-Ser-Gly− − 132 Glp-Lys-Gly − − 133 Glp-Phe-Gly − − 134 Glp-Glu-Gly − − 135Glp-Thr-Gly − − 136 Glp-Ile-Gly − − 137 Glp-Tyr-Gly − − 138 Glp-His-Gly− − 139 Glp-Asn-Gly − − 140 Glp-Arg-Gly − − 141 Glp-Gly-Gly − − 142Glp-Trp-Gly − − 143 Glp-Asp-Gly − − 144 Glp-Met-Gly − − 145 Glp-Leu-Gly− − 146 Glp-Pro-Gln − − 147 Glp-Pro-Asn + − 148 Glp-Pro-Gln − − 149Glp-Pro-Ser − − 150 Glp-Pro-Pro + − 151 Glp-Pro-Trp − − 152 Glp-Pro-Asp− − 153 Glp-Pro-His − − 154 Glp-Pro-Leu − − 155 Glp-Pro-Arg − − 156Glp-Pro-Val − − 157 Glp-Pro-Lys − − 158 Glp-Pro-Glu − − 159 Glp-Pro-Phe− − 160 Glp-Pro-Ile + − 161 Glp-Pro-Met + − 162 Glp-Pro-Tyr + − Met(O)2= Methioninedioxide, Cha = cyclohexyl-Ala

1. A peptide permeability inhibitor consisting of an amino acid sequenceselected from the group consisting of SEQ ID NOs: 1-162, wherein saidpeptide permeability inhibitor inhibits translocation of agliadin-derived peptide across a biological barrier.
 2. The peptide ofclaim 1, wherein the peptide does not consist of an amino acid sequenceselected from the group consisting of SEQ ID NOs: 15, 24 and
 25. 3. Thepeptide of claim 1, wherein the peptide consists of an amino acidsequence selected from the group consisting of SEQ ID NOs: 1-5, 10-17,19-23, 27, 32, 34, 36, 48, 49, 55, 58, 67-77, 79-85, 87, 88, 91, 92, 94,98-104, 106, 110, 111, 113-125, 127, 128, 147, 150, and 160-162.
 4. Amethod of inhibiting gliadin-derived peptide translocation across abiological barrier comprising contacting said barrier with a peptidepermeability inhibitor consisting of an amino acid sequence selectedfrom the group consisting of SEQ ID NOs: 1-162.
 5. The method of claim4, wherein the peptide does not consist of an amino acid sequenceselected from the group consisting of SEQ ID NOs: 15, 24 and
 25. 6. Themethod of claim 4, wherein the peptide consists of an amino acidsequence selected from the group consisting of SEQ ID NOs: 1-5, 10-17,19-23, 27, 32, 34, 36, 48, 49, 55, 58, 67-77, 79-85, 87, 88, 91, 92, 94,98-104, 106, 110, 111, 113-125, 127, 128, 147, 150, and 160-162.
 7. Acomposition for inhibiting gliadin-derived peptide translocation acrossa biological barrier, wherein said composition comprises the peptidepermeability inhibitor of claim
 1. 8-9. (canceled)
 10. A method forinhibiting gliadin-derived peptide translocation across a biologicalbarrier comprising administering to a subject in need thereof thecomposition of claim 7 in an amount sufficient to inhibit saidgliadin-derived peptide translocation. 11-30. (canceled)
 31. A method oftreating a patient with celiac disease, comprising administering to thepatient a composition comprising a peptide that inhibits translocationof a gliadin-derived peptide across a biological barrier.
 32. The methodof claim 31, wherein said composition comprises peptide consisting of anamino acid sequence selected from the group consisting of SEQ ID NOs:1-162.
 33. The method of claim 32, wherein the peptide does not consistof an amino acid sequence selected from the group consisting of SEQ IDNOs: 15, 24 and
 25. 34. The method of claim 32, wherein the peptideconsists of an amino acid sequence selected from the group consisting ofSEQ ID NOs: 1-5, 10-17, 19-23, 27, 32, 34, 36, 48, 49, 55, 58, 67-77,79-85, 87, 88, 91, 92, 94, 98-104, 106, 110, 111, 113-125, 127, 128,147, 150, and 160-162.
 35. The method of claim 31, wherein saidcomposition further comprises an additional therapeutic agent selectedfrom the group consisting of aminosalicylates, corticosteroids,immunomodulators, antibiotics, cytokines, chemokines and biologictherapeutics. 36-45. (canceled)